



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

**0 206 733**  
**A1**

⑫

## EUROPEAN PATENT APPLICATION

⑰ Application number: 86304656.1

⑱ Date of filing: 17.06.86

⑤ Int. Cl.: **C 12 N 15/00, C 07 K 13/00,**  
**C 07 H 21/04, C 12 N 1/20,**  
**C 12 P 21/02**  
**// (C12R1/19, 1:185)**

③ Priority: 17.06.85 US 745524

④ Date of publication of application: 30.12.86  
Bulletin 86/52

⑥ Designated Contracting States: AT BE CH DE FR GB IT LI  
LU NL SE

⑦ Applicant: GENEX CORPORATION, 16020, Industrial  
Drive, Gaithersburg Maryland 20877 (US)

⑧ Inventor: Burns, Alexander Lee, 1012 Julian Place,  
Rockville, Maryland 20852 (US)

⑨ Representative: Holmes, Michael John et al, Frank B.  
Dehn & Co. European Patent Attorneys Imperial  
House 15-19 Kingsway, London, WC2B 6UZ, (GB)

⑤④ Cloned human serum albumin gene.

⑤⑦ Disclosed are a synthetic human serum albumin gene,  
plasmids containing the gene, and microorganisms trans-  
formed by those plasmids.

**EP 0 206 733 A1**

CLONED HUMAN SERUM ALBUMIN GENE

This invention relates to a method for synthesising a human serum albumin gene. This invention further relates to a plasmid containing a cloned human serum albumin gene and a microorganism transformed with such a plasmid.

Human serum albumin (sometimes referred to hereinafter as HSA) is the major protein component of plasma. The protein is produced in the liver and is primarily responsible for maintaining normal osmolarity in the bloodstream. It also is capable of binding and transporting various small molecules via the blood.

HSA is administered in various clinical situations. Shock and burn victims, for instance, usually require doses of HSA to restore blood volume and thus ameliorate some of the symptoms associated with trauma. Persons suffering from hypoproteinemia or erythroblastosis fetalis also are likely to require treatment with serum albumin.

To date, HSA is produced primarily as a by-product from the fractionation of donated blood. A drawback to this is that the cost and supply of blood can vary widely. The blood also may contain undesirable agents such as hepatitis virus. It therefore would be advantageous to develop an alternative source of HSA.

It accordingly is an object of this invention to produce human serum albumin in microorganisms. It is a further object of this invention to so produce HSA economically. It also is an object of this invention to

develop a cloning procedure that can be applied to other serum proteins.

Brief Description of the Figures

5 Figure 1 shows a partial restriction map of a full-length HSA cDNA clone isolated by the procedures described herein.

10 Figure 2 shows the DNA sequence of the 5'→3' strand of the non-coding and coding regions of the full length HSA cDNA, as well as the amino acid sequence specified by the DNA sequence.

Figure 3 shows an A<sub>260</sub> profile of sucrose gradient fractions of mRNA. Fraction group B was used as the template in the synthesis of HSA cDNA.

15 Figure 4 shows pGX401, a recombinant plasmid containing a full length HSA cDNA insert.

Figure 5 shows the DNA sequence in the region of codon 97 for HSA sequences derived from three different human livers.

20 According to one aspect of the present invention, we provide a synthetic human serum albumin gene. The term "synthetic" as used herein should be understood to include DNA sequences produced by use of recombinant DNA techniques and/or chemical synthesis.

25 In accordance with the present invention, a novel human serum albumin (HSA) gene has been cloned and bacterial expression of the gene is described. The nucleotide sequence of the full length HSA gene and the amino acid sequence of the polypeptide specified by that gene also are reported herein.

30 The procedure more fully described hereinafter which has been used to prepare an HSA-producing microorganism can be divided into the following stages: (1) obtaining HSA mRNA from a suitable source, e.g. by recovery and isolation of the HSA mRNA from HSA producing cells, (2) in vitro synthesis of  
35 complementary DNA (cDNA), using the mRNA as a template and conversion of the cDNA to the double-stranded form and (3) insertion of the double-stranded

cDNA into a suitable cloning vector and transformation of microbial cells with that cloning vector. The procedures described herein resulted in the preparation of a "full-length" cloned HSA cDNA.

5       Eukaryotic genes are contained in the chromosomal DNA of cell nuclei. This chromosomal DNA exists in a compact nucleoprotein complex called chromatin. Eukaryotic chromosomal DNA contains intervening sequences (introns) within the coding sequences (exons), which  
10       would not permit correct expression in bacteria. For this reason a preferred method for producing contiguous coding blocks of a particular protein involves the use of messenger RNA (mRNA). Messenger RNA has a ribonucleotide sequence corresponding to the gene of interest without  
15       the introns and conveniently can be recovered from eukaryotic cells that produce the protein specified by the gene.

      Human serum albumin mRNA can be recovered in useful quantities from human liver cells. The HSA mRNA produced  
20       by the liver cells is complementary to one of the two strands of the HSA gene and may be employed as a template for the synthesis of complementary DNA (cDNA) as herein-  
after described. To effectively utilize the mRNA for the synthesis of cDNA, it advantageously is recovered from  
25       the cells in relatively pure form. The guanidine thiocyanate/guanidine hydrochloride extraction procedure described by McCandliss et al., Methods in Enzymology  
79:51 (1981), advantageously may be used to recover and purify the HSA mRNA. RNA is inherently less stable than  
30       DNA, and is particularly subject to degradation by ribonucleases that are present in the cells. Therefore, mRNA recovery procedures generally employ means for rapidly inactivating any ribonucleases which are present.

      In general, recovery of total RNA is initiated by  
35       disrupting the cells in the presence of a ribonuclease-inactivating substance. Disruption of the cells may be

accomplished by subjecting the cells to a lysing reagent, freezing/thawing, or mechanical disruption; preferably a combination thereof. A mixture of guanidine thiocyanate and a reducing agent, such as mercaptoethanol, has been  
5 found to function effectively as a ribonuclease inactivator (McCandliss, et al., supra).

After disruption of the cells, the solid cell debris is removed, e.g. by centrifugation, and the RNA is precipitated from the resulting clarified solution.  
10 Precipitation is effected by known techniques, such as adding a water-miscible alcohol, e.g. ethanol, to the solution in a precipitating amount. The RNA then is resuspended in a guanidine hydrochloride solution and precipitated with ethanol for two successive cycles. At  
15 this point the RNA is undegraded and free of proteins and DNA.

The next step is the separation of mRNA from the total precipitated RNA. Human serum albumin mRNA is polyadenylated, therefore, it readily can be separated  
20 from non-adenylated RNA by affinity chromatography with oligodeoxythymidylate (oligo dT) cellulose (Aviv, H., et al., Proc. Natl. Acad. Sci. USA 69: 1408 (1972); McCandliss, et al., supra). Total RNA can be applied to a column in an approximately 0.5 M NaCl containing solu-  
25 tion. Under these conditions only poly A<sup>+</sup> RNA binds to the oligo dT cellulose and can be removed specifically by washing the column in a salt free solution.

To enrich the preparation for HSA mRNA, the poly A<sup>+</sup>RNA can be fractionated according to size by sucrose  
30 gradient centrifugation. Activity of the RNA in the various gradient fractions can be verified by in vitro translation in a reticulocyte lysate (Pelham, H., et al. Eur. J. Biochem. 67:247 (1976)) and by electrophoretic analysis of the protein products (Laemmli, U., Nature  
35 227:680 (1970)).

Once a poly A<sup>+</sup>RNA fraction able to synthesize proteins the size of HSA has been isolated, it can be used to provide a template for cDNA synthesis. This procedure involves enzymatically constructing double-stranded DNA, which has a nucleotide base pair sequence identical to the coding sequence of the original chromosomal gene. The cDNA does not contain any noninformational segments (introns) within the coding region which might be present in the eukaryotic gene, and thus can ultimately be transcribed and translated in prokaryotic systems.

Synthesis of HSA cDNA employs the enzymes reverse transcriptase, Klenow fragment of DNA polymerase I and S1 nuclease (Kacian, D., et al., Proc. Nat. Acad. Sci. USA 73:2191 (1976); McCandliss, R., et al., Methods in Enzymology 79, p. 601 (1981)). Reverse transcriptase catalyzes the synthesis of a single strand of DNA from deoxynucleoside triphosphates on the mRNA template. The poly r(A) tail of the mRNA permits oligo (dT) (of about 12 to 18 nucleotides) to be used as a primer for cDNA synthesis. The use of a radioactively-labelled deoxynucleoside triphosphate facilitates monitoring of the synthesis reaction. Generally, a <sup>32</sup>P-containing deoxynucleoside triphosphate advantageously may be used for this purpose. The cDNA synthesis generally is conducted by combining the mRNA, the deoxynucleoside triphosphates, the oligo (dT) and the reverse transcriptase in a buffered solution. This solution is incubated at an elevated temperature, e.g., about 40-50°C, for a time sufficient to allow formation of the cDNA copy, e.g. about 5-20 minutes. The conditions of the reaction are essentially as described by Kacian, D.L., et al., supra. After incubation, disodium ethylenediaminetetraacetic acid (hereinafter EDTA) is added to the solution, and the solution is extracted with phenol:chloroform (1:1 by

vol.). The aqueous phase is advantageously purified by gel filtration chromatography, and the cDNA-mRNA complex in the eluate is precipitated with alcohol.

The mRNA can be selectively hydrolyzed in the presence of the cDNA with dilute sodium hydroxide (about 0.1 M) at an elevated temperature, e.g., about 60-80°C for about 15-30 minutes. Neutralization of the alkaline solution and alcohol precipitation yields a single-stranded cDNA copy.

The single-stranded cDNA copy has been shown to have a 5'-poly (dT) tail, and to have a 3' terminal hairpin structure, which provides a short segment of duplex DNA (Efstratiadis, A., et al., Cell, 7, 279 (1976)). This 3' hairpin structure can act as a primer for the synthesis of a complementary DNA strand. Synthesis of this complementary strand is conducted using the Klenow fragment of DNA polymerase I (Klenow, H., et al., Eur. J. Biochem., 22, 371 (1971)) in a reaction mixture containing the deoxynucleoside triphosphates. The duplex cDNA recovered by this procedure has a 3' loop, resulting from the 3' hairpin structure of the single-stranded cDNA copy. This 3' loop can be cleaved by digestion with the enzyme, S1 nuclease, using essentially the procedure of McCandliss et al., Methods in Enzymology 79:601 (1981). The S1 nuclease digest may be extracted with phenol-chloroform, and the resulting cDNA precipitated from the aqueous phase with alcohol.

The intact double-stranded DNA (about 2000 base pairs) corresponding to a human serum albumin gene can be isolated by, for example, sucrose gradient centrifugation, using the procedure of McCandliss supra p. 51. In order to determine the sizes of the DNA in the sucrose gradient, aliquots of the gradient fractions are electrophoresed in a polyacrylamide gel with molecular weight markers. The resulting gel is first stained with

ethidium bromide to visualize the markers and then autoradiographed to detect the radioactive cDNA. The fractions of the gradient containing DNA molecules larger than 1000 base pairs are pooled and the DNA is precipitated with ethanol.

For purposes of amplification and selection, the double-stranded cDNA gene prepared as described above is generally inserted into a suitable cloning vector, which is used for transforming appropriate host cells.

Suitable cloning vectors include various plasmids and phages, with plasmids being preferred in this case. The criteria for selecting a cloning vector include its size, its capability for replicating in the host cells, the presence of selectable genes, and the presence of a site for insertion of the gene. With respect to its size, the vector is advantageously relatively small, to permit large gene insertions, and so as not to divert large amounts of cellular nutrients and energy to the production of unwanted macromolecules. The vector also includes an intact replicon which remains functional after insertion of the gene. This replicon preferably directs the desired mode of replication of the plasmid, i.e., multiple copies or a single copy per cell, or a controllable number of copies per cell. Genes specifying one or more phenotypic properties, preferably antibiotic resistance, facilitate selection of transformants. The insertion site is advantageously a unique restriction site for a restriction endonuclease. A cloning vector meeting all of these criteria is the plasmid pBR322. The cDNA can be conveniently inserted into this plasmid by a homopolymeric tailing technique. Homopolymer tails are added to the 3'-hydroxyl groups of the human serum albumin double-stranded cDNA gene, by reaction with an appropriate deoxynucleoside triphosphate, in the presence of terminal deoxynucleotidyl transferase. The plasmid is



opened by digestion with the appropriate endonuclease, and complementary homopolymer tails are added to the 3'-hydroxyl groups of the opened plasmid, using the homopolymeric tailing technique. Appropriate reaction conditions have been described for the addition of dC residues to ds cDNA (McCandliss, R., et al., page 601 supra; Roychoudhury, R., et al., Nucleic Acids Research 3:101 (1976)) and of dG residues to PstI treated pBR322 (Maeda, S., Methods in Enzymology 79:607 (1981)). In a preferred embodiment, however, the molar excess of dXTPs to 3' ends is in the range of 3000 to 5000. Progress of the reactions is monitored until the chain length is approximately 15. The tailed cDNA and plasmids are recovered, e.g., by phenol extraction followed by alcohol precipitation. The homopolymeric ends of the two DNAs are complementary and will anneal together under appropriate conditions to yield a recombinant plasmid containing the HSA gene (Maeda, S., Methods in Enzymology 79:611 (1981)).

A suitable strain of E.coli may be transformed with this recombinant plasmid, using essentially the method of Lederberg, J. Bacteriology 119:1072 (1974) and be maintained indefinitely.

Generally, several hundred to several thousand clones are produced by these procedures and can be screened for the presence of the HSA gene with, for example, rat serum albumin cDNA. A nick translated (Maniatis, T., et al., Proc. Natl. Acad. Sci. USA 72:3961 (1975)) rat cDNA having 85% homology with human cDNA can be used to hybridize to plasmid cDNA attached to nitrocellulose filters (Grunstein, M., et al., Proc. Natl. Acad. Sci. USA 72:396 (1975), Southern, E.M. J. Mol. Biol., 98:503 (1975)). In this procedure, DNA from each colony (or from groups of colonies) is fixed to discrete zones of a nitrocellulose filter and denatured.

Alternatively, the DNA can be electrophoresed in a gel prior to fixing on a filter. A solution of the radioactively labeled rat cDNA is applied thereto under hybridizing conditions. Unhybridized rat cDNA is washed from the filter, and colonies containing DNA to which the rat cDNA hybridized are identified by autoradiography. One positive clone was identified but found to be an incomplete HSA cDNA by DNA sequencing. A portion of this HSA cDNA was then nick translated in order to rescreen the entire bank of clones. Ninety positive hybridization signals were thus obtained.

Positive clones may be cultivated on suitable growth media to obtain ample quantities of cells from which to extract the plasmid DNA. The plasmid DNA is extracted, using conventional techniques, such as disruption of the cells, followed by phenol extraction, and alcohol precipitation. The plasmid and chromosomal DNAs may be separated, e.g. by electrophoresis or cesium chloride equilibrium centrifugation. Plasmid DNA containing inserts of about 1500 to 2000 base pairs are selected for further characterization.

The cloned gene can be excised from the plasmid DNA and then characterized by sequencing analysis (Sanger, F., et al., Proc. Natl. Acad. Sci. USA 74:5463 (1977); Maxam, A., et al., Proc. Natl. Acad. Sci. USA 74:560 (1977)).

By these procedures a prepro-HSA clone has been isolated. An E. coli HB101 culture transformed with the plasmid containing this prepro-HSA gene has been deposited with the U.S. Department of Agriculture Northern Regional Research Laboratory in Peoria, Illinois, as NRRL No. B-15784. A diagnostic partial restriction map of this HSA gene insert is shown in Figure 1 of the drawings and Figure 2 shows the 5'-->3'

strand of the non-coding and coding regions, along with the amino acid sequence specified by the gene.

The cloned prepro-HSA coding sequence consists of 2050 base pairs excluding the oligo dC tails added to the cDNA. The gene  
5 has noncoding regions at the 5' end (base pairs 1-31) and at the 3' end (base pairs 1858-2050). The 5' end of the coding region (32- 103 base pairs) includes a 24 amino-acid leader (an 18- amino-acid "pre" sequence followed by a 6-amino-acid "pro" sequence) and the mature  
10 human serum albumin protein is specified by the region from base pair number 104 to base pair number 1858.

As used in Figure 2 and elsewhere herein, the abbreviations have the following standard meaning:

	A	=	deoxyadenyl
15	T	=	thymidyl
	G	=	deoxyguanyl
	C	=	deoxycytosyl
	GLY	=	glycine
	ALA	=	alanine
20	VAL	=	valine
	LEU	=	leucine
	ILE	=	isoleucine
	SER	=	serine
	THR	=	threonine
25	PHE	=	phenylalanine
	TYR	=	tyrosine
	TRP	=	tryptophan
	CYS	=	cysteine
	MET	=	methionine
30	ASP	=	aspartic acid
	GLU	=	glutamic acid
	LYS	=	lysine
	ARG	=	arginine
	HIS	=	histidine
35	PRO	=	proline

GLN = glutamine

ASN = asparagine

It will be appreciated that because of the degeneracy of the genetic code, the nucleotide sequence of the gene can vary substantially. For example, portions or all of the gene could be chemically synthesized to yield DNA having a different nucleotide sequence than that shown in Figure 2, yet the amino acid sequence would be preserved, provided that the proper codon-amino acid assignments were observed. Having established the nucleotide sequence of the human serum albumin gene and the amino acid sequence of the protein, the gene of the present invention is not limited to a particular nucleotide sequence, but includes all variations thereof as permitted by the genetic code.

It is believed that the amino acid sequence set forth in Figure 2 and claimed herein represents a genomic HSA allele that is widespread in the human population, in contrast to the sequences previously published in the scientific literature. Polymorphism is known for HSA. Protein electrophoresis has revealed over twenty genetic variants of HSA (Weitkamp et al., Ann. Hum. Genet. London 36:381 (1973)). Two differing amino acid sequences have been reported previously. See Lawn, R.M., et al., Nucl. Acids Res. 9:6103 (1981) and Dugiaczyk, A., et al., PNAS 79:71 (1982). The DNA sequence of Figure 2 differs from each of these published sequences. Although some of the differences occur in third base position of codons or in the noncoding regions, and as such do not cause amino acid changes, conflicting nucleotide sequence data suggest different amino acids at positions 97 and 396. In Figure 2, the amino acid represented by codon 97 (GAG) is glutamic acid. The same was reported by Lawn, et al., supra. Dugiaczyk, however, reported that codon to be GGG (glycine). Codon 396 in

Figure 2, also is designated GAG (glutamic acid). Dugiaczyk reported the same; however, Lawn reported codon 396 to be AAG (lysine). Thus, each of the three DNA sequences would encode a different polypeptide. Example

• 5 IV below sets forth the procedures followed to determine that these differences represented true protein polymorphism and not merely experimental artifacts.

The present invention has been described in connection with the use of E. coli as the bacterial host for recombinant DNA containing the HSA gene, but skilled

10 molecular biologists will appreciate that other gram-negative bacteria, such as Pseudomonas; gram-positive bacteria, such as Bacillus; higher unicellular organisms, such as yeasts and fungi, and mammalian cells can be

15 employed for cloning and/or expression of the HSA gene.

The invention is further illustrated by reference to the following examples, which are not intended to be limiting.

#### EXAMPLE I

##### 20 Isolation of HSA mRNA from Human Liver Tissue

Messenger RNA (mRNA) was isolated from human liver tissue taken from a 10-year-old accident victim. Extreme care was taken throughout the procedures to avoid ribonuclease contamination of the mRNA preparation.

25 These measures included the use of new, sterile laboratory glassware, treatment of solutions with diethylpyrocarbonate when appropriate, followed by autoclaving, keeping the preparation cold when possible and using gloves to avoid contact of the preparation with skin.

30 Frozen human liver tissue (10.5 grams) was homogenized in 210 mls lysis solution (4M guanidine thiocyanate/0.1M Tris-HCl, pH 7.5/0.1M 2-mercaptoethanol) using a Virtis homogenizer. Cellular debris was pelleted by

centrifugation at 8750 rpm, 4°C, for 10 minutes in a Sorvall GSA rotor, and the supernatant was transferred to a new centrifuge bottle. To the supernatant were added 0.04 volume 1M acetic acid and 0.5 volume 95% ethanol.

5 After 2 hours at -20°C, the mixture was centrifuged at 7500 rpm, 10 minutes, 4°C and the pellet resuspended in 50 mls wash solution (6M guanidine hydrochloride/10mM Na<sub>2</sub>·EDTA, pH 7.0/10mM dithiothreitol.) Centrifugation at 5500 rpm, 10 minutes, pelleted particulate debris, and

10 the supernatant was transferred to a new centrifuge bottle. To the supernatant were added 0.04 volume 1M acetic acid and 0.5 volume 95% ethanol. After 2 hours at -20°C, the mixture was centrifuged at 7200 rpm 20 minutes. The pellet was resuspended in 20 mls wash

15 solution, and 0.04 volume 1M acetic acid and 0.5 volume 95% ethanol were added. The mixture was kept at -20°C for 12 hours, then centrifuged at 8,000 rpm for 10 minutes at 4°C in a Sorvall SS-34 rotor. The pellet was resuspended in 15 mls sterile distilled H<sub>2</sub>O (dH<sub>2</sub>O) and

20 extracted with an equal volume of (4:1) chloroform: butanol. The aqueous phase was transferred to a fresh tube and 0.1 volume 2.4 M sodium acetate and 2.5 volumes 95% ethanol were added. After 2.5 hours at -20°C, the RNA was pelleted by centrifugation and the pellet was

25 resuspended in 2 mls sterile dH<sub>2</sub>O). A total of 19.2 mg RNA was recovered.

mRNA was then separated from the total RNA using generally, the oligo(dT)-cellulose affinity chromatography procedure described in Aviv et al.. supra

30 and McCandliss, et al., supra. A column of 5 grams oligo(dT)-cellulose was washed with one column volume 0.1M NaOH to denature any ribonuclease present, then equilibrated with high salt buffer (10mM Tris-HCl, pH 7.4/0.5M NaCl/0.5% sodium dodecyl sulfate). The total

35 RNA preparation, dissolved in two mls dH<sub>2</sub>O above, was

heated at 70°C for 1 minute, then cooled on ice to room temperature. Next, 0.1 volume 5M NaCl, 0.04 ml 0.5M Tris-HCl, pH 7.5, and 0.1 ml 10% sodium dodecyl sulfate (SDS) were added to the RNA. 8 mls high salt buffer were then added to the RNA and the solution was applied to the column with a flow rate of about 10 drops/minute. After the sample had passed through, unbound RNA was washed from the column with high salt buffer. Fractions (1/2 ml each) were collected and the optical density at 260 nm ( $A_{260}$ ) of each fraction was measured in a spectrophotometer. The column was washed until the  $A_{260}$  readings of fractions dropped below 0.05. Undesired RNA was further washed from the column with low salt buffer (10mM Tris-HCl, pH 7.4/0.2M NaCl/0.1% SDS) and fractions were collected as above until the  $A_{260}$  had dropped to 0.05.

Next, the mRNA was eluted from the column with elution buffer (10mM Tris-HCl, pH 7.4/1mM EDTA/0.1% SDS) and 1 ml fractions were collected until the  $A_{260}$  was less than 0.05. The first 15 fractions (those having the highest  $OD_{260}$  readings) were pooled and the mRNA was precipitated by adding 0.1 volume 2.4M sodium acetate and 2.5 volumes 95% ethanol, and placing at -20°C for 12 hours. The eluted mRNA was then pelleted by centrifugation and resuspended in 800  $\mu$ l elution buffer. After heating the resuspended pellet at 70°C for 90 seconds then cooling on ice; 0.1 volume 5M NaCl and 0.05 volume 10% SDS were added.

The eluted mRNA prepared above was then further purified by passage over a second oligo(dT)-cellulose column. A column containing 0.1 gram oligo(dT) cellulose was washed with NaOH, then with high salt buffer as previously described. The RNA was applied to the column and fractions were collected with high salt, low salt, and elution buffers as with the first column. The peak

fractions from the elution buffer step were pooled and the twice-purified mRNA was precipitated and pelleted as before.

5 The mRNA was then size-fractionated on a 12-ml sucrose gradient as described in McCandliss et al., Methods in Enzymology, 79, pp. 56-58. A 5-20% sucrose gradient was prepared in gradient buffer (0.02M sodium acetate, pH 5.6) and chilled at 4°C for 3 hours. 100µg of the mRNA was resuspended in 100µl gradient buffer, 10 heated at 80°C for 2 minutes, quick-cooled in an ice bath, then layered on top of the gradient. A second 5-20% gradient had E. coli 16 and 23S rRNA (100µg total) loaded on it to serve as molecular weight markers.

The two gradients were centrifuged in a Beckman 15 SW40 rotor at 38,000 rpm for 12.5 hr at 4°C. Fractions of about 0.5 ml were then collected and the  $A_{260}$  measured (fraction #1 is that collected from the bottom of the gradient tube.) The  $A_{260}$  peak was divided into 6 groups of fractions, groups A through F as shown in Figure 3. 20 The fractions in each group were pooled and the mRNA precipitated with 0.1 volume 2.4 M sodium acetate and 2.5 volumes 95% ethanol.

Fraction groups containing mRNA which encodes protein of the size expected for HSA were identified by 25 in vitro translation using a rabbit reticulocyte lysate kit (available from Bethesda Research Laboratories and used according to manufacturer's instructions) supplemented with  $^{35}\text{S}$  methionine. A reaction mixture for each fraction group contained the components necessary for 30 translation of the mRNA into radioactively-labeled proteins which were visualized by electrophoresis on a 12.5% polyacrylamide/SDS gel, followed by fluorography.

The fluorogram showed a prominent protein band of the size expected for HSA (68,000 daltons) among the 35 translation products of fraction groups B and C. Group B



had a much lower percentage of protein products in undesirable low molecular weight range so the mRNA in group B was chosen for use as a template in the synthesis of cDNA.

5

## EXAMPLE II

Synthesis of HSA cDNA

Generally, the cDNA synthesis procedure of McCandliss et al., Methods in Enzymology, 79, pp. 601-607 (1981) was used. Incorporation of a radioactively  
10 labeled deoxynucleotide allowed monitoring of the synthesis and calculation of yields at each step.

The first strand of cDNA was synthesized on the mRNA template, using oligo-dT as a primer, as follows.

Prepared mix and kept on ice:

15	0.5 M Tris-HCl, pH 8.3	20 $\mu$ l
	1.4 M KCl	10 $\mu$ l
	0.25M MgCl <sub>2</sub>	8 $\mu$ l
	0.05M dATP, pH 7.0	2 $\mu$ l
	0.05M TTP, pH 7.0	2 $\mu$ l
20	0.05M dCTP, pH 7.0	2 $\mu$ l
	0.05M dGTP, pH 7.0	2 $\mu$ l
	0.01M dithiothreitol	4 $\mu$ l
	sterile distilled H <sub>2</sub> O	45 $\mu$ l
	aqueous label, $\alpha^{32}$ P-dCTP (10 $\mu$ Ci/ $\mu$ l)	5 $\mu$ l
25		100 $\mu$ l

## Added remaining components:

	oligo(dT) <sub>12-18</sub> (250 µg/ml)	20 µl
	actinomycin D (500 µg/ml, aqueous)	16 µl
	10 µg mRNA, "B" fraction	20 µl
5	sterile dH <sub>2</sub> O	37 µl
	*AMV reverse transcriptase (16u/µl)	<u>7 µl</u>
	Total volume:	200 µl

10 \*Avian myeloblastosis virus (AMV) reverse transcriptase is kept at -80°C and thawed briefly to add as last component

The reaction mixture was kept on ice 5 minutes and 2 µl were removed and counted in ASC scintillation fluid in order to determine the specific activity of the dCTP. The reaction mixture was then incubated 10 minutes at 15 46°C. 20 µl 0.2M EDTA pH 8.0 was added to stop the reaction, and the mixture was then extracted with an equal volume (1:1) phenol:chloroform.

0.14 volume 80% glycerol was added and sample was chromatographed on a 0.7 x 17 cm. Sephadex G-100 column. 20 Once the sample had entered the column, G100 buffer (10mM Tris-HCl, pH 8.0/1mM EDTA/100mM NaCl) was added to the column and 5-drop (about 275 µl) fractions were collected. The radioactive fractions were "Cerenkov counted" and the cDNA fractions comprising the peak counts per minute were 25 pooled. The mRNA/cDNA hybrids were precipitated by adding 0.1 volume 2.4M sodium acetate and 2.5 volumes 95% ethanol, placing in a dry ice/ethanol bath for 30 minutes, then pelleting by centrifugation at 10,000 rpm, 4°C, for 20 minutes. The pellet was resuspended in 300 µl 30 0.1M NaOH and heated at 70°C for 20 minutes to hydrolyze the RNA, leaving single-stranded cDNA. 30 µl 1M HCl were added to neutralize the solution. The DNA was precipitated by adding 5 µg tRNA, 1/10 volume 2.4M sodium acetate, and 2.5 volumes 95% ethanol, placing in a dry

ice-ethanol bath 10 minutes, and centrifuging in a microfuge 10 minutes at 4°C.

The pellet was resuspended in the following mix:

40μl 0.5M potassium phosphate, pH 7.4  
5        8μl 0.25M MgCl<sub>2</sub>  
         2μl 0.1M dithiothreitol  
         1μl 0.05M dATP, pH 7.0  
         1μl 0.05M dCTP, pH 7.0  
         1μl 0.05M dGTP, pH 7.0  
10       1μl 0.05M TTP, pH 7.0  
         124μl sterile dH<sub>2</sub>O  
         178μl

Next, added 22μl DNA polymerase I Klenow fragment (5μ/μl, available from Boehringer-Mannheim.)

15       The reaction mixture was then incubated in a 15°C water bath for 12 hours. 20μl 0.2M EDTA pH 8.0 was added to stop the reaction and the mixture was extracted with an equal volume (1:1) phenol:chloroform. 0.14 volume glycerol was added to the aqueous phase.

20       The sample, which now contains double-stranded cDNA, was run over a Sephadex G100 column and the peak cDNA fractions were pooled and precipitated as before. The double-stranded DNA has a 3' "hairpin loop" as previously described, which was removed with S1 nuclease  
25 as follows. The pellet was resuspended in 72 μl sterile distilled water and then 18 μl 5X S1 buffer (1M NaCl/0.25M sodium acetate, pH 4.5/5mM ZnSO<sub>4</sub>/2.5% glycerol) were added. An enzyme mix was prepared by adding 2.5 μl (50 units) of S1 nuclease (20μg/μl) to 47.5  
30 μl 1X S1 buffer. 10μl of enzyme mix was added to the 90μl DNA solution then incubated at 37°C 20 minutes. Addition of 20 μl 0.2M sodium EDTA stopped the reaction, and the reaction mixture was extracted with an equal volume (1:1) phenol:chloroform. The aqueous phase was

loaded onto a 5-25% sucrose gradient and spun at 38,000 rpm 17.5 hours 5°C in an ultracentrifuge.

One-ml fractions were collected and "Cerenkov counted." Fractions were pooled with fractions 1-6, 7-9, and 10-12 comprising the 3 pools. Fraction #1 was the fraction taken from the bottom of the gradient. DNA was precipitated by adding 0.1 volume 2.4M sodium acetate, 1-2 µg tRNA, and 2.5 volumes 95% ethanol to each pool, then placing them at -20°C overnight. The DNA was pelleted by centrifugation at 25K for 30 minutes at 4°C. After slightly dessicating pellets, the DNA from each pool was resuspended in 200µl dH<sub>2</sub>O and precipitated again with ethanol and sodium acetate. Pellets were resuspended in 22µl dH<sub>2</sub>O and spun in a microfuge 5 minutes to pellet insoluble matter. 2µl of each cDNA-containing supernatant were analyzed by electrophoresis on a 6% polyacrylamide gel. Autoradiography of the gel showed that the DNA in the pool of fractions 1-6 had an average size of 1100 base-pairs (bp) and included DNA in the 200 bp range and this pool was chosen for addition of "polyC tails" to the 3' ends of the cDNA, using, generally, the homopolymeric tailing procedure described in McCandliss et al., page 601 et seq., supra. A 5000 molar excess of dCTP over 3' cDNA ends was found to give good results.

The reaction mixture was as follows:

20µl cDNA (about 43 ng)  
- <sup>3</sup>H dCTP (645 pmol, lyophilized)  
2.4µl 10X TdT buffer\*  
1.6µl dH<sub>2</sub>O  
24.0µl

\*10X TdT buffer = 1.4M potassium cacodylate/0.3M Tris-HCl, pH 7.0/10mM CoCl<sub>2</sub>/1mM DTT)

The reaction mixture was preincubated to 37°C for 2 minutes, 2µl were removed for use in calculations, then 2µl (6.66 units) P-L Biochemicals terminal deoxynucleo-

tidyl transferase were added and incubation at 37°C was continued for 5 minutes. Calculations based on incorporation of <sup>3</sup>H dCTP indicated that the 3'ends of the cDNA now carried "polyC tails" an average of 14 nucleotides in length. 80μl T.E. buffer (10mM Tris-HCl, pH 7.6/1mM EDTA) were added to the DNA and the solution was extracted with an equal volume of (1:1) phenol:chloroform. The organic phase was then retracted with 100μl dH<sub>2</sub>O and the two aqueous phases were combined.

The C-tailed double-stranded cDNA was then annealed to plasmid pBR322 DNA which had been linearized with the restriction endonuclease PstI, then "G-tailed" by the homopolymeric tailing method. The complementary single-stranded C and G "tails" will anneal, producing recombinant plasmids with cDNA inserts at the PstI site.

200μl cDNA, C-tailed (39.2 ng)

10.5μl pBR322-PstI, G-tailed (302 ng)

93μl 10X buffer\*

626.5 μl dH<sub>2</sub>O

930μl

The reaction mix was placed in an insulated water bath at 70°C. The bath was then transferred to a 37°C room and allowed to cool slowly to 37°C overnight, then transferred to room temperature, where the bath cooled to 30°C over several hours. The reaction mixture was then stored at 4°C.

\*(10X annealing buffer = 1.5M NaCl/100mM Tris-HCl, pH7.5/10mM EDTA)

E. coli HB101 cells were made competent for transformation by known calcium chloride treatment procedures. 200μl aliquots of competent HB101 cells were each combined with 40μl of the annealing reaction mixture and kept on ice 20 minutes, then heat-shocked at 42°C for 2 minutes. 2.8 mls Luria broth were added to

each tube and incubated at 37°C for 1 hour. The tubes' contents were aliquoted (1/2 ml aliquots) into tubes containing Luria broth plus 0.7% agar, and then were poured onto Luria broth-agar plates containing 25µg/ml tetracycline and incubated at 37°C until colonies appeared.

Only those cells transformed by pBR322 (with or without a cDNA insert) can grow on tetracycline plates. Approximately 2500 transformant colonies grew on the plates.

### EXAMPLE III

#### Isolation of a Full-Length HSA cDNA

The transformants were initially screened with a rat serum albumin (RSA) cDNA fragment. The RSA cDNA fragment was obtained from a pBR322 plasmid containing a 2000 bp RSA cDNA insert. This recombinant plasmid is similar to, but contains a longer cDNA insert than, the plasmid prAlbI described in Proc. Nat'l. Acad. Sci. USA, 76, 4370 (1979). A 1480 bp rat serum albumin (RSA) fragment was isolated by digesting the plasmid carrying the RSA cDNA with the restriction endonuclease BstEII (all restriction endonucleases used in these examples were used according to manufacturer's specifications.) The fragment was then radioactively labeled with  $\alpha^{32}\text{P}$  by the "nick translation" procedure (Maniatis et al. PNAS USA, 72:3961 (1975)).

About 80 10-ml cultures of individual transformants were grown and plasmid DNA was isolated by known plasmid "mini-prep" procedures. The partially purified plasmid DNAs were subjected to electrophoresis on 0.8% agarose gels. The DNA was transferred from the gels to nitrocellulose filters using the "Southern blotting"

technique (Southern, E.M. J. Molec. Biology 98, 503 (1975)).

The nitrocellulose filters were immersed for 2 hours at 42°C in prehybridization solution (50% formamide/5X SSC\*/0.05M NaPO<sub>4</sub>, pH 6.5/5X Denhardt's\*/100µg/ml salmon sperm DNA). The filters were then transferred into hybridization solution (50% formamide/10% dextran sulfate/5X SSC/20mM NaPO<sub>4</sub>, pH 6.5/1X Denhardt's/50µg/ml salmon sperm DNA.) The nick-translated 1480bp RSA fragment prepared above was heated at 100°C for 5 minutes, then quick cooled on ice, and this probe was added to the hybridization solution at 2 X 10<sup>5</sup> cpm probe per ml of solution. The filters were incubated in the hybridization solution at 42°C for 18 hours, then washed twice in 2XSSC and once in 0.1X SSC at room temperature.

Autoradiography of the filters revealed non-specific hybridization of the probe to all plasmid DNAs. Therefore, several Southern blot filters were washed in 2XSSC at various temperatures from 65°C to 80°C. DNA from one plasmid on a filter washed at 65°C hybridized strongly with the probe.

DNA sequencing revealed that the "positive" clone, called 6C3, was a partial-length human serum albumin clone. Plasmid DNA was isolated from a culture of 6C3 and digested with the restriction endonuclease PstI. One of the resulting HSA cDNA fragments, about 475bp in length, was isolated and "nick translated" for use as a

\*50X Denhardt's stock = 1% polyvinylpyrrolidone/1% ficoll/1% bovine serum albumin.

1XSSC = 150mM NaCl/15mM sodium citrate, pH 6.8 with citric acid

probe. The entire bank of approximately 2500 clones was screened with this probe using a modification of the hybridization procedure of Grunstein et al., supra.

5 The transformant colonies were individually picked from the plates into separate wells in 96-well microtiter plates containing Luria broth plus 0.2% glucose plus 25µg/ml tetracycline and incubated at 37°C overnight. Using a transfer device with 48 metal prongs, samples of each culture were transferred to two Luria  
10 broth/agar/tetracycline plates, one plate previously overlaid with a nitrocellulose filter, and incubated at 37°C 2 days. The filters were then placed successively on Whatman filter paper soaked in one of the following solutions: 0.5M NaOH; 1M Tris, pH7.4; 1M Tris, pH7.4;  
15 2XSSC; 90% ethanol, and 90% ethanol (in that order, 7 minutes per solution.) The nitrocellulose filters were then baked in vacuo at 80°C for 2 hours.

Prehybridization and hybridization procedures were as described above, except that the three washes were at  
20 room temperature. 90 positive hybridization signals were detected by autoradiography. Some of the "positive clones" were further analyzed by restriction analysis (e.g. PstI digestion) and hybridization of "Southern blots" as above.

25 A clone bearing a full length HSA cDNA was identified and confirmed by DNA sequencing. The recombinant plasmid containing this HSA cDNA insert was termed pGX401 and is shown in figure 4. A partial restriction map of the HSA cDNA is shown in Figure 1,  
30 while Figure 2 shows the DNA sequence (5'+3' strand) of the cloned gene and the amino acid sequence it specifies.

A sample of E. coli HB101 transformed with pGX401 has been deposited at the U.S. Dept. of Agriculture



Northern Regional Research Center in Peoria, Illinois.  
under accession number NRRL B-15784.

## EXAMPLE IV

5        DNA Sequence Analysis of HSA cDNA Prepared  
         from Human Liver Samples Taken from  
         Different Individuals

         In comparing the DNA sequence of the HSA cDNA  
insert in pGX401 (Example III) with the cDNA sequences  
published by Lawn et al., supra, and Dugaiczky et al.,  
10    supra, two codon differences were found that predict  
amino acid differences. The pGX401 sequence and the  
sequence reported by Lawn et al. indicated that codon 97  
of the mature protein was GAG (glutamic acid), while  
Dugaiczky et al. reported it to be GGG (glycine). In the  
15    pGX401 sequence and the sequence reported by Dugaiczky  
codon 396 also was reported to be GAG (glutamic acid),  
and Lawn et al. reported that codon to be AAG (lysine).

         To gain some insight into whether these differences  
represented true protein polymorphisms or merely  
20    experimental artifacts, the DNA sequence in the regions  
of codons 97 and 396 was determined for several new  
independent HSA genes.

         Messenger RNA (mRNA) was isolated from normal human  
liver tissue taken from four different individuals. The  
25    procedures of Example I were followed except that sucrose  
gradient fractionation of oligo (dT)-cellulose-purified  
mRNA was omitted. Double stranded cDNA was synthesized  
from this mRNA template by the procedures described in  
Example II and poly(dC) "tails" were added according to  
30    Deng and Wu, NAR 9:4123, 1981.

         The vector into which the dC-tailed cDNA was  
inserted was plasmid pGX1066. This plasmid comprises the  
phage  $\lambda$ tR<sub>1</sub> transcription terminator upstream of a bank of  
ten closely-spaced unique restriction sites, which in  
turn is upstream of the  $\lambda$ 4S transcription terminator.

E. coli strain GX1170 [F' leu hsdR thi supE gal-1,2 lac xyl ara trpC9830 lacI9] transformed with pGX1066 has been deposited with the American Type Culture Collection, Rockville, Maryland, as ATCC No. 39955.

5 Plasmid pGX1066 was linearized with PstI and poly(dG) tails were added using the homopolymeric tailing method described by Deng and Wu (Nucleic Acids Res., 9: 4173 (1981)). The vector DNA and cDNA were then annealed as described in Example II. E. coli strain DH1 cells  
10 [F-, endA1, hsdR17 (R<sub>k</sub>-, M<sub>k</sub>-), supE44, thi1,  $\lambda^-$ , recA1, gyrA96, relA1] were made competent and transformed with the annealing reaction mix. Both E. coli strain DH1 and the transformation procedure used are described by D. Hanahan (J. Molec. Biol., 166: 557 (1983)). Transfor-  
15 mants were plated on LM plates (1% (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 10mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 1.5% (w/v) Bacto agar) with 35µg/ml ampicillin added.

Transformed E. coli colonies were screened for the presence of HSA sequences by Grunstein-Hogness filter  
20 hybridization (Gergen et al., 1979, Nuc. Acids. Res. 7:2115; Wallace et al., 1981, Nuc. Acids Res. 9:879) using kinased oligomers or nick-translated HSA cDNA fragments as probes. For identification of clones carrying HSA cDNA containing codon 396, a synthetic  
25 oligonucleotide, 5' TTGTACTCTCCAAGCTGC 3', corresponding to codons 397-402 (and the last nucleotide of codon 396) was used. For detection of clones carrying HSA cDNA containing codon 97, either of two synthetic  
oligonucleotides, 5' TCTCTTCATTGTCATGAAAAGC 3',  
30 corresponding to codons 126-132 (and one nucleotide of codon 133), or 5' TTCTTGTTTTCACACAGC 3', corresponding to codons 90 (last 2 nucleotides) - 95, or a nick-translated HSA fragment (derived from pGX401), corresponding to  
35 codons -1 to 364 was used. Upon identification of clones containing the HSA sequence of interest, restriction

fragments were subcloned into an M13 phage. HSA cDNA-carrying phage were identified by screening plaques according to the procedure of Benton and Davis (Science, 196:180 (1977)). The DNA sequence was determined with these M13 clones by the dideoxy method (Biggin et al., Proc. Nat. Acad. Sci., U.S.A. 80:3963 (1983)).

By the procedures described above, transformants containing HSA cDNA that included codon 396 were derived from all four human livers. Transformants containing HSA cDNA that included codon 97 were derived from only two of the four livers. The DNA sequence in all cases (including 60 to 100 base pairs on each side of the codon in question) matched the sequence determined for pGX401.

Messenger RNA then was isolated from normal human liver samples taken from two more individuals, and the sequence at codon 97 was determined using a modification of the Sanger sequencing procedure in which reverse transcriptase was used to copy the single-stranded RNA template. A synthetic oligonucleotide, 5' TGTCTCTTCATTGTCATGAAAAGC 3', corresponding to codons 126-133, was used as a primer. The mRNA, purified by oligo (dT)-cellulose chromatography as previously described, was incubated in a reaction volume of 2  $\mu$ l containing 10 mM Tris  $\cdot$  HCl (pH 8.3), 140 mM KCl, 10 mM  $MgCl_2$ , 20 mM  $\beta$ -mercaptoethanol, 1.6 mM dNTP, 0.2 mM ddNTP, 250 ng RNA, 5 ng kinased primer and 1.88 units reverse transcriptase (Life Sciences, Inc.). After overlaying the solution with 4  $\mu$ l of mineral oil the reaction was incubated at 42°C for fifteen minutes and was terminated by the addition of 7  $\mu$ l of 250 mM  $Na_2$  EDTA. The mineral oil was extracted with ether and removed with a drawn-out pasteur pipette. Formamide loading buffer was added to the samples prior to electrophoresis on a urea sequencing gel. The gels were run until the bromphenol blue tracking dye had migrated to

the bottom. They then were dried under vacuum and exposed to X-ray film with two intensifying screens for periods between twelve hours and several days.

5 The HSA sequence at codon 97 for both liver samples was identical to the sequence at codon 97 in pGX401. (See Figure 5.) The reliability of the technique to determine nucleotide sequence from mRNA was evaluated using polyA<sup>+</sup> RNA prepared from the liver that was the source of the cDNA originally cloned in pGX401. The  
10 results (Figure 5) showed that the sequence determined in this manner was identical to the sequence originally determined in pGX401.

CLAIMS FOR THE DESIGNATED STATES: BE, DE, FR, IT,  
LU, NL, SE, CH and UK

1. A synthetic gene coding for human serum albumin.
2. An isolated human serum albumin gene.
3. An isolated prepro-human serum albumin gene.
4. A human serum albumin gene as claimed in claim 1,  
comprising the following deoxyribonucleotide sequence  
which corresponds to the indicated amino acid sequence:

Asp	Ala	His	Lys	Ser	Glu	Val	Ala
G A Y	G C X	C A Y	A A M	Q R S	G A M	G T X	G C X
His	Arg	Phe	Lys	Asp	Leu	Gly	Glu
C A Y	L G N	T T Y	A A M	G A Y	Y T Z	G G X	G A M
Glu	Asn	Phe	Lys	Ala	Leu	Val	Leu
G A M	A A Y	T T Y	A A M	G C X	Y T Z	G T X	Y T Z
Ile	Ala	Phe	Ala	Gln	Tyr	Leu	Gln
A T H	G C X	T T Y	G C X	C A M	T A Y	Y T Z	C A M
Gln	Cys	Pro	Phe	Glu	Asp	His	Val
C A M	T G Y	C C X	T T Y	G A M	G A Y	C A Y	G T X
Lys	Leu	Val	Asn	Glu	Val	Thr	Glu
A A M	Y T Z	G T X	A A Y	G A M	G T X	A C X	G A M
Phe	Ala	Lys	Thr	Cys	Val	Ala	Asp
T T Y	G C X	A A M	A C X	T G Y	G T X	G C X	G A Y
Glu	Ser	Ala	Glu	Asn	Cys	Asp	Lys
G A M	Q R S	G C X	G A M	A A Y	T G Y	G A Y	A A M
Ser	Leu	His	Thr	Leu	Phe	Gly	Asp
Q R S	Y T Z	C A Y	A C X	Y T Z	T T Y	G G X	G A Y
Lys	Leu	Cys	Thr	Val	Ala	Thr	Leu
A A M	Y T Z	T G Y	A C X	G T X	G C X	A C X	Y T Z
Arg	Glu	Thr	Tyr	Gly	Glu	Met	Ala
L G N	G A M	A C X	T A Y	G G X	G A M	A T G	G C X
Asp	Cys	Cys	Ala	Lys	Gln	Glu	Pro
G A Y	T G Y	T G Y	G C X	A A M	C A M	G A M	C C X

Glu G A M	Arg L G N	Asn A A Y	Glu G A M	Cys T G Y	Phe T T Y	Leu Y T Z	Gln C A M
His C A Y	Lys A A M	Asp G A Y	Asp G A Y	Asn A A Y	Pro C C X	Asn A A Y	Leu Y T Z
Pro C C X	Arg L G N	Leu Y T Z	Val G T X	Arg L G N	Pro C C X	Glu G A M	Val G T X
Asp G A Y	Val G T X	Met A T G	Cys T G Y	Thr A C X	Ala G C X	Phe T T Y	His C A Y
Asp G A Y	Asn A A Y	Glu G A M	Glu G A M	Thr A C X	Phe T T Y	Leu Y T Z	Lys A A M
Lys A A M	Tyr T A Y	Leu Y T Z	Tyr T A Y	Glu G A M	Ile A T H	Ala G C X	Arg L G N
Arg L G N	His C A Y	Pro C C X	Tyr T A Y	Phe T T Y	Thr A C X	Ala G C X	Pro C C X
Glu G A M	Leu Y T Z	Leu Y T Z	Phe T T Y	Phe T T Y	Ala G C X	Lys A A M	Arg L G N
Tyr T A Y	Lys A A M	Ala G C X	Ala G C X	Phe T T Y	Thr A C X	Glu G A M	Cys T G Y
Cys T G Y	Ala G C X	Gln C A M	Ala G C X	Asp G A Y	Lys A A M	Ala G C X	Ala G C X
Cys T G Y	Leu Y T Z	Phe T T Y	Pro C C X	Lys A A M	Leu Y T Z	Asp G A Y	Glu G A M
Leu Y T Z	Arg L G N	Asp G A Y	Glu G A M	Gly G G X	Lys A A M	Ala G C X	Ser Q R S
Ser Q R S	Ala G C X	Lys A A M	Gln C A M	Arg L G N	Leu Y T Z	Lys A A M	Cys T G Y
Ala G C X	Ser Q R S	Leu Y T Z	Gln C A M	Lys A A M	Phe T T Y	Gly G G X	Glu G A M
Arg L G N	Ala G C X	Phe T T Y	Lys A A M	Ala G C X	Trp T G G	Ala G C X	Val G T X
Ala G C X	Arg L G N	Leu Y T Z	Ser Q R S	Gln C A M	Arg L G N	Phe T T Y	Pro C C X
Lys A A M	Ala G C X	Glu G A M	Phe T T Y	Ala G C X	Glu G A M	Val G T X	Ser Q R S
Lys A A M	Phe T T Y	Val G T X	Thr A C X	Asp G A Y	Leu Y T Z	Thr A C X	Lys A A M
Val G T X	His C A Y	Thr A C X	Glu G A M	Cys T G Y	Cys T G Y	His C A Y	Gly G G X

30

Asp G A Y	Leu Y T Z	Leu Y T Z	Glu G A M	Cys T G Y	Ala G C X	Asp G A Y	Asp G A Y
Arg L G N	Ala G C X	Asp G A Y	Leu Y T Z	Ala G C X	Lys A A M	Tyr T A Y	Ile A T H
Cys T G Y	Glu G A M	Asn A A Y	Gln C A M	Asp G A Y	Ser Q R S	Ile A T H	Ser Q R S
Ser Q R S	Lys A A M	Leu Y T Z	Lys A A M	Glu G A M	Cys T G Y	Cys T G Y	Glu G A M
Lys A A M	Pro C C X	Leu Y T Z	Phe T T Y	Glu G A M	Lys A A M	Ser Q R S	His C A Y
Cys T G Y	Ile A T H	Ala G C X	Glu G A M	Val G T X	Glu G A M	Asn A A Y	Asp G A Y
Glu G A M	Met A T G	Pro C C X	Ala G C X	Asp G A Y	Phe T T Y	Pro C C X	Ser Q R S
Phe T T Y	Ala G C X	Val G T X	Asp G A Y	Phe T T Y	Val G T X	Glu G A M	Ser Q R S
Lys A A M	Asp G A Y	Val G T X	Cys T G Y	Lys A A M	Asn A A Y	Tyr T A Y	Ala G C X
Glu G A M	Ala G C X	Lys A A M	Asp G A Y	Val G T X	Phe T T Y	Leu Y T Z	Gly G G X
Met A T G	Phe T T Y	Phe T T Y	Tyr T A Y	Glu G A M	Tyr T A Y	Ala G C X	Arg L G N
Arg L G N	His C A Y	Pro C C X	Asp G A Y	Tyr T A Y	Ser Q R S	Val G T X	Val G T X
Leu Y T Z	Leu Y T Z	Leu Y T Z	Arg L G N	Leu Y T Z	Ala G C X	Lys A A M	Thr A C X
Tyr T A Y	Glu G A M	Thr A C X	Thr A C X	Leu Y T Z	Glu G A M	Lys A A M	Cys T G Y
Cys T G Y	Ala G C X	Ala G C X	Ala G C X	Asp G A Y	Pro C C X	His C A Y	Glu G A M
Cys T G Y	Tyr T A Y	Ala G C X	Lys A A M	Val G T X	Phe T T Y	Asp G A Y	Glu G A M
Phe T T Y	Lys A A M	Pro C C X	Pro C C X	Val G T X	Glu G A M	Glu G A M	Pro C C X

Gln	Asn	Phe	Ile	Lys	Gln	Asn	Cys
C A M	A A Y	T T Y	A T H	A A M	C A M	A A Y	T G Y
Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu
G A M	Y T Z	T T Y	G A M	C A M	Y T Z	G G X	G A M
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Phe
T A Y	A A M	T T Y	C A M	A A Y	G C X	Y T Z	T T Y
Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro
G T X	L G N	T A Y	A C X	A A M	A A M	G T X	C C X
Gln	Leu	Ser	Thr	Pro	Thr	Leu	Val
C A M	Y T Z	Q R S	A C X	C C X	A C X	Y T Z	G T X
Glu	Val	Ser	Arg	Asn	Leu	Gly	Lys
G A M	G T X	Q R S	L G N	A A Y	Y T Z	G G X	A A M
Val	Gly	Ser	Lys	Cys	Cys	Lys	His
G T X	G G X	Q R S	A A M	T G Y	T G Y	A A M	C A Y
Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys
C C X	G A M	G C X	A A M	L G N	A T G	C C X	T G Y
Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val
G C X	G A M	G A Y	T A Y	Y T Z	Q R S	G T X	G T X
Leu	Asn	Gln	Leu	Cys	Val	Leu	His
Y T Z	A A Y	C A M	Y T Z	T G Y	G T X	Y T Z	C A Y
Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg
G A M	A A M	A C X	C C X	G T X	Q R S	G A Y	L G N
Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser
G T X	A C X	A A M	T G Y	T G Y	A C X	G A M	Q R S
Leu	Val	Asn	Arg	Arg	Pro	Gly	Phe
Y T Z	G T X	A A Y	L G N	L G N	C C X	G G X	T T Y
Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr
Q R S	G C X	Y T Z	G A M	G T X	G A Y	G A M	A C X
Tyr	Val	Pro	Lys	Glu	Phe	Asn	Ala
T A Y	G T X	C C X	A A M	G A M	T T Y	A A Y	G C X
Glu	Thr	Phe	Thr	Phe	His	Ala	Asp
G A M	A C X	T T Y	A C X	T T Y	C A Y	G C X	G A Y
Ile	Cys	Thr	Leu	Ser	Glu	Lys	Glu
A T H	T G Y	A C X	Y T Z	Q R S	G A M	A A M	G A M



32

Arg	Gln	Ile	Lys	Lys	Glu	Thr	Ala
L G N	C A M	A T H	A A M	A A M	G A M	A C X	G C X
Leu	Val	Glu	Leu	Val	Lys	His	Lys
Y T Z	G T X	G A M	Y T Z	G T X	A A M	C A Y	A A M
Pro	Lys	Ala	Thr	Lys	Glu	Glu	Leu
C C X	A A M	G C X	A C X	A A M	G A M	G A M	Y T Z
Lys	Ala	Val	Met	Asp	Asp	Phe	Ala
A A M	G C X	G T X	A T G	G A Y	G A Y	T T Y	G C X
Ala	Phe	Val	Glu	Lys	Cys	Cys	Lys
G C X	T T Y	G T X	G A M	A A M	T G Y	T G Y	A A M
Ala	Asp	Asp	Lys	Glu	Thr	Cys	Phe
G C X	G A Y	G A Y	A A M	G A M	A C X	T G Y	T T Y
Ala	Glu	Glu	Gly	Lys	Lys	Leu	Val
G C X	G A M	G A M	G G X	A A M	A A M	Y T Z	G T X
Ala	Ala	Ser	Glu	Ala	Val	Leu	Gly
G C X	G C X	Q R S	G A M	G C X	G T X	Y T Z	G G X
Leu							
Y T Z	T A A						

wherein, the 5' to 3' strand, beginning with the amino terminus and the amino acids for which each triplet codes are shown, and wherein the abbreviations have the following standard meanings:

A is deoxyadenyl

T is thymidyl

G is deoxyguanyl

C is deoxycytosyl

X is A, T, C or G

Y is T or C

When Y is C, Z is A, T, C or G

When Y is T, Z is A or G

H is A, T or C

Q is T or A

When Q is T, R is C and S is A, T, C or G

When Q is A, R is G and S is T or C

5. A prepro-serum albumin gene as claimed in claim 1 comprising the following deoxyribonucleotide sequence:

	Met	Lys	Trp	Val	Thr	Phe		
	A T G	A A M	T G G	G T X	A C X	T T Y		
5	Ile	Ser	Leu	Leu	Phe	Leu	Phe	
	A T H	Q R S	Y T Z	Y T Z	T T Y	Y T Z	T T Y	
	Ser	Ser	Ala	Tyr	Ser	Arg	Gly	
	Q R S	Q R S	G C X	T A Y	Q R S	L G N	G G X	
10	Val	Phe	Arg	Arg	Asp	Ala	His	Lys
	G T X	T T Y	L G N	L G N	G A Y	G C X	C A Y	A A M

34

Ser	Glu	Val	Ala	His	Arg	Phe	Lys
Q R S	G A M	G T X	G C X	C A Y	L G N	T T Y	A A M
Asp	Leu	Gly	Glu	Glu	Asn	Phe	Lys
G A Y	Y T Z	G G X	G A M	G A M	A A Y	T T Y	A A M
Ala	Leu	Val	Leu	Ile	Ala	Phe	Ala
G C X	Y T Z	G T X	Y T Z	A T H	G C X	T T Y	G C X
Gln	Tyr	Leu	Gln	Gln	Cys	Pro	Phe
C A M	T A Y	Y T Z	C A M	C A M	T G Y	C C X	T T Y
Glu	Asp	His	Val	Lys	Leu	Val	Asn
G A M	G A Y	C A Y	G T X	A A M	Y T Z	G T X	A A Y
Glu	Val	Thr	Glu	Phe	Ala	Lys	Thr
G A M	G T X	A C X	G A M	T T Y	G C X	A A M	A C X
Cys	Val	Ala	Asp	Glu	Ser	Ala	Glu
T G Y	G T X	G C X	G A Y	G A M	Q R S	G C X	G A M
Asn	Cys	Asp	Lys	Ser	Leu	His	Thr
A A Y	T G Y	G A Y	A A M	Q R S	Y T Z	C A Y	A C X
Leu	Phe	Gly	Asp	Lys	Leu	Cys	Thr
Y T Z	T T Y	G G X	G A Y	A A M	Y T Z	T G Y	A C X
Val	Ala	Thr	Leu	Arg	Glu	Thr	Tyr
G T X	G C X	A C X	Y T Z	L G N	G A M	A C X	T A Y
Gly	Glu	Met	Ala	Asp	Cys	Cys	Ala
G G X	G A M	A T G	G C X	G A Y	T G Y	T G Y	G C X
Lys	Gln	Glu	Pro	Glu	Arg	Asn	Glu
A A M	C A M	G A M	C C X	G A M	L G N	A A Y	G A M
Cys	Phe	Leu	Gln	His	Lys	Asp	Asp
T G Y	T T Y	Y T Z	C A M	C A Y	A A M	G A Y	G A Y
Asn	Pro	Asn	Leu	Pro	Arg	Leu	Val
A A Y	C C X	A A Y	Y T Z	C C X	L G N	Y T Z	G T X
Arg	Pro	Glu	Val	Asp	Val	Met	Cys
L G N	C C X	G A M	G T X	G A Y	G T X	A T G	T G Y
Thr	Ala	Phe	His	Asp	Asn	Glu	Glu
A C X	G C X	T T Y	C A Y	G A Y	A A Y	G A M	G A M
Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr
A C X	T T Y	Y T Z	A A M	A A M	T A Y	Y T Z	T A Y

Glu G A M	Ile A T H	Ala G C X	Arg L G N	Arg L G N	His C A Y	Pro C C X	Tyr T A Y
Phe T T Y	Thr A C X	Ala G C X	Pro C C X	Glu G A M	Leu Y T Z	Leu Y T Z	Phe T T Y
Phe T T Y	Ala G C X	Lys A A M	Arg L G N	Tyr T A Y	Lys A A M	Ala G C X	Ala G C X
Phe T T Y	Thr A C X	Glu G A M	Cys T G Y	Cys T G Y	Ala G C X	Gln C A M	Ala G C X
Asp G A Y	Lys A A M	Ala G C X	Ala G C X	Cys T G Y	Leu Y T Z	Phe T T Y	Pro C C X
Lys A A M	Leu Y T Z	Asp G A Y	Glu G A M	Leu Y T Z	Arg L G N	Asp G A Y	Glu G A M
Gly G G X	Lys A A M	Ala G C X	Ser Q R S	Ser Q R S	Ala G C X	Lys A A M	Gln C A M
Arg L G N	Leu Y T Z	Lys A A M	Cys T G Y	Ala G C X	Ser Q R S	Leu Y T Z	Gln C A M
Lys A A M	Phe T T Y	Gly G G X	Glu G A M	Arg L G N	Ala G C X	Phe T T Y	Lys A A M
Ala G C X	Trp T G G	Ala G C X	Val G T X	Ala G C X	Arg L G N	Leu Y T Z	Ser Q R S
Gln C A M	Arg L G N	Phe T T Y	Pro C C X	Lys A A M	Ala G C X	Glu G A M	Phe T T Y
Ala G C X	Glu G A M	Val G T X	Ser Q R S	Lys A A M	Phe T T Y	Val G T X	Thr A C X
Asp G A Y	Leu Y T Z	Thr A C X	Lys A A M	Val G T X	His C A Y	Thr A C X	Glu G A M
Cys T G Y	Cys T G Y	His C A Y	Gly G G X	Asp G A Y	Leu Y T Z	Leu Y T Z	Glu G A M
Cys T G Y	Ala G C X	Asp G A Y	Asp G A Y	Arg L G N	Ala G C X	Asp G A Y	Leu Y T Z
Ala G C X	Lys A A M	Tyr T A Y	Ile A T H	Cys T G Y	Glu G A M	Asn A A Y	Gln C A M
Asp G A Y	Ser Q R S	Ile A T H	Ser Q R S	Ser Q R S	Lys A A M	Leu Y T Z	Lys A A M

36

Glu	Cys	Cys	Glu	Lys	Pro	Leu	Phe
G A M	T G Y	T G Y	G A M	A A M	C C X	Y T Z	T T Y
Glu	Lys	Ser	His	Cys	Ile	Ala	Glu
G A M	A A M	Q R S	C A Y	T G Y	A T H	G C X	G A M
Val	Glu	Asn	Asp	Glu	Met	Pro	Ala
G T X	G A M	A A Y	G A Y	G A M	A T G	C C X	G C X
Asp	Phe	Pro	Ser	Phe	Ala	Val	Asp
G A Y	T T Y	C C X	Q R S	T T Y	G C X	G T X	G A Y
Phe	Val	Glu	Ser	Lys	Asp	Val	Cys
T T Y	G T X	G A M	Q R S	A A M	G A Y	G T X	T G Y
Lys	Asn	Tyr	Ala	Glu	Ala	Lys	Asp
A A M	A A Y	T A Y	G C X	G A M	G C X	A A M	G A Y
Val	Phe	Leu	Gly	Met	Phe	Phe	Tyr
G T X	T T Y	Y T Z	G G X	A T G	T T Y	T T Y	T A Y
Glu	Tyr	Ala	Arg	Arg	His	Pro	Asp
G A M	T A Y	G C X	L G N	L G N	C A Y	C C X	G A Y
Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg
T A Y	Q R S	G T X	G T X	Y T Z	Y T Z	Y T Z	L G N
Leu	Ala	Lys	Thr	Tyr	Glu	Thr	Thr
Y T Z	G C X	A A M	A C X	T A Y	G A M	A C X	A C X
Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala
Y T Z	G A M	A A M	T G Y	T G Y	G C X	G C X	G C X
Asp	Pro	His	Glu	Cys	Tyr	Ala	Lys
G A Y	C C X	C A Y	G A M	T G Y	T A Y	G C X	A A M
Val	Phe	Asp	Glu	Phe	Lys	Pro	Pro
G T X	T T Y	G A Y	G A M	T T Y	A A M	C C X	C C X
Val	Glu	Glu	Pro	Gln	Asn	Phe	Ile
G T X	G A M	G A M	C C X	C A M	A A Y	T T Y	A T H
Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu
A A M	C A M	A A Y	T G Y	G A M	Y T Z	T T Y	G A M
Gln	Leu	Gly	Glu	Tyr	Lys	Phe	Gln
C A M	Y T Z	G G X	G A M	T A Y	A A M	T T Y	C A M
Asn	Ala	Leu	Phe	Val	Arg	Tyr	Thr
A A Y	G C X	Y T Z	T T Y	G T X	L G N	T A Y	A C X

Lys A A M	Lys A A M	Val G T X	Pro C C X	Gln C A M	Leu Y T Z	Ser Q R S	Thr A C X
Pro C C X	Thr A C X	Leu Y T Z	Val G T X	Glu G A M	Val G T X	Ser Q R S	Arg L G N
Asn A A Y	Leu Y T Z	Gly G G X	Lys A A M	Val G T X	Gly G G X	Ser Q R S	Lys A A M
Cys T G Y	Cys T G Y	Lys A A M	His C A Y	Pro C C X	Glu G A M	Ala G C X	Lys A A M
Arg L G N	Met A T G	Pro C C X	Cys T G Y	Ala G C X	Glu G A M	Asp G A Y	Tyr T A Y
Leu Y T Z	Ser Q R S	Val G T X	Val G T X	Leu Y T Z	Asn A A Y	Gln C A M	Leu Y T Z
Cys T G Y	Val G T X	Leu Y T Z	His C A Y	Glu G A M	Lys A A M	Thr A C X	Pro C C X
Val G T X	Ser Q R S	Asp G A Y	Arg L G N	Val G T X	Thr A C X	Lys A A M	Cys T G Y
Cys T G Y	Thr A C X	Glu G A M	Ser Q R S	Leu Y T Z	Val G T X	Asn A A Y	Arg L G N
Arg L G N	Pro C C X	Gly G G X	Phe T T Y	Ser Q R S	Ala G C X	Leu Y T Z	Glu G A M
Val G T X	Asp G A Y	Glu G A M	Thr A C X	Tyr T A Y	Val G T X	Pro C C X	Lys A A M
Glu G A M	Phe T T Y	Asn A A Y	Ala G C X	Glu G A M	Thr A C X	Phe T T Y	Thr A C X
Phe T T Y	His C A Y	Ala G C X	Asp G A Y	Ile A T H	Cys T G Y	Thr A C X	Leu Y T Z
Ser Q R S	Glu G A M	Lys A A M	Glu G A M	Arg L G N	Gln C A M	Ile A T H	Lys A A M
Lys A A M	Glu G A M	Thr A C X	Ala G C X	Leu Y T Z	Val G T X	Glu G A M	Leu Y T Z
Val G T X	Lys A A M	His C A Y	Lys A A M	Pro C C X	Lys A A M	Ala G C X	Thr A C X
Lys A A M	Glu G A M	Glu G A M	Leu Y T Z	Lys A A M	Ala G C X	Val G T X	Met A T G
Asp G A Y	Asp G A Y	Phe T T Y	Ala G C X	Ala G C X	Phe T T Y	Val G T X	Glu G A M

38

Lys	Cys	Cys	Lys	Ala	Asp	Asp	Lys
A A M	T G Y	T G Y	A A M	G C X	G A Y	G A Y	A A M
Glu	Thr	Cys	Phe	Ala	Glu	Glu	Gly
G A M	A C X	T G Y	T T Y	G C X	G A M	G A M	G G X
Lys	Lys	Leu	Val	Ala	Ala	Ser	Glu
A A M	A A M	Y T Z	G T X	G C X	G C X	Q R S	G A M
Ala	Val	Leu	Gly	Leu			
G C X	G T X	Y T Z	G G X	Y T Z	T A A		

wherein the 5' and 3' strand, beginning with the amino terminus, and the amino acids for which each triplet codes are shown, and wherein the abbreviations are defined as in claim 4.

6. A human serum albumin gene as claimed in claim 4 comprising the following deoxyribonucleotide sequence:

GAT GCA CAC AAG AGT GAG GTT GCT CAT CGG TTT AAA GAT TTG  
 GGA GAA GAA AAT TTC AAA GCC TTG GTG TTG ATT GCC TTT GCT  
 CAG TAT CTT CAG CAG TGT CCA TTT GAA GAT CAT GTA AAA TTA  
 GTG AAT GAA GTA ACT GAA TTT GCA AAA ACA TGT GTT GCT GAT  
 GAG TCA GCT GAA AAT TGT GAC AAA TCA CTT CAT ACC CTT TTT  
 GGA GAC AAA TTA TGC ACA GTT GCA ACT CTT CGT GAA ACC TAT  
 GGT GAA ATG GCT GAC TGC TGT GCA AAA CAA GAA CCT GAG AGA  
 AAT GAA TGC TTC TTG CAA CAC AAA GAT GAC AAC CCA AAC CTC  
 CCC CGA TTG GTG AGA CCA GAG GTT GAT GTG ATG TGC ACT GCT  
 TTT CAT GAC AAT GAA GAG ACA TTT TTG AAA AAA TAC TTA TAT  
 GAA ATT GCC AGA AGA CAT CCT TAC TTT TAT GCC CCG GAA CTC  
 CTT TTC TTT GCT AAA AGG TAT AAA GCT GCT TTT ACA GAA TGT  
 TGC CAA GCT GCT GAT AAA GCT GCC TGC CTG TTG CCA AAG CTC  
 GAT GAA CTT CGG GAT GAA GGG AAG GCT TCG TCT GCC AAA CAG  
 AGA CTC AAG TGT GCC AGT CTC CAA AAA TTT GGA GAA AGA GCT  
 TTC AAA GCA TGG GCG GTG GCT CGC CTG AGC CAG AGA TTT CCC  
 AAA GCT GAG TTT GCA GAA GTT TCC AAG TTA GTG ACA GAT CTT  
 ACC AAA GTC CAC ACG GAA TGC TGC CAT GGA GAT CTG CTT GAA  
 TGT GCT GAT GAC AGG GCG GAC CTT GCC AAG TAT ATC TGT GAA  
 AAT CAA GAT TCG ATC TCC AGT AAA CTG AAG GAA TGC TGT GAA

AAA CCT CTG TTG GAA AAA TCC CAC TGC ATT GCC GAA GTG GAA  
 AAT GAT GAG ATG CCT GCT GAC TTG CCT TCA TTA GCT GCT GAT  
 TTT GTT GAA AGT AAG GAT GTT TGC AAA AAC TAT GCT GAG GCA  
 AAG GAT GTC TTC CTG GGC ATG TTT TTG TAT GAA TAT GCA AGA  
 AGG CAT CCT GAT TAC TCT GTC GTG CTG CTG CTG AGA CTT GCC  
 AAG ACA TAT GAA ACC ACT CTA GAG AAG TGC TGT GCC GCT GCA  
 GAT CCT CAT GAA TGC TAT GCC AAA GTG TTC GAT GAA TTT AAA  
 CCT CCT GTG GAA GAG CCT CAG AAT TTA ATC AAA CAA AAT TGT  
 GAG CTT TTT GAG CAG CTT GGA GAG TAC AAA TTC CAG AAT GCG  
 CTA TTA GTT CGT TAC ACC AAG AAA GTA CCC CAA GTG TCA ACT  
 CCA ACT CTT GTA GAG GTC TCA AGA AAC CTA GGA AAA GTG GGC  
 AGC AAA TGT TGT AAA CAT CCT GAA GCA AAA AGA ATG CCC TGT  
 GCA GAA GAC TAT CTA TCC GTG GTC CTG AAA CAG TTA TGT GTG  
 TTG CAT GAG AAA ACG CCA GTA AGT GAC AGA GTC ACC AAA TGC  
 TGC ACA GAA TCC TTG GTG AAC AGG CGA CCA TGC TTT TCA GCT  
 CTG GAA GTC GAT GAA ACA TAC GTT CCC AAA GAG TTT AAT GCT  
 GAA ACA TTC ACC TTC CAT GCA GAT ATA TGC ACA CTT TCT GAG  
 AAG GAG AGA CAA ATC AAG AAA CAA ACT GCA CTT GTT GAG CTC  
 GTG AAA CAC AAG CCC AAG GCA ACA AAA GAG CAA CTG AAA GCT  
 GTT ATG GAT GAT TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG  
 GCT GAC GAT AAG GAG ACC TGC TTT GCC GAG GAG GGT AAA AAA  
 CTT GTT GCT GCA AGT CAA GCT GCC TTA GGC TTA TAA

wherein the 5' to 3' strand, beginning with the amino terminus is shown, and wherein the abbreviations are defined as in claim 4.

7. A human prepro-serum albumin gene as claimed in claim 5

comprising the following deoxyribonucleotide sequence:

ATG AAG TGG GTA ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC  
 TCG GCT TAT TCC AGG GGT GTG TTT CGT CGA GAT GCA CAC AAG  
 AGT GAG GTT GCT CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT  
 TTC AAA GCC TTG GTG TTG ATT GCC TTT GCT CAG TAT CTT CAG  
 CAG TGT CCA TTT GAA GAT CAT GTA AAA TTA GTG AAT GAA GTA  
 ACT GAA TTT GCA AAA ACA TGT GTT GCT GAT GAG TCA GCT GAA



AAT TGT GAC AAA TCA CTT CAT ACC CTT TTT GGA GAC AAA TTA  
TGC ACA GTT GCA ACT CTT CGT GAA ACC TAT GGT GAA ATG GCT  
GAC TGC TGT GCA AAA CAA GAA CCT GAG AGA AAT GAA TGC TTC  
TTG CAA CAC AAA GAT GAC AAC CCA AAC CTC CCC CGA TTG GTG  
AGA CCA GAG GTT GAT GTG ATG TGC ACT GCT TTT CAT GAC AAT  
GAA GAG ACA TTT TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA  
AGA CAT CCT TAC TTT TAT GCC CCG GAA CTC CTT TTC TTT GCT  
AAA AGG TAT AAA GCT GCT TTT ACA GAA TGT TGC CAA GCT GCT  
GAT AAA GCT GCC TGC CTG TTG CCA AAG CTC GAT GAA CTT CGG  
GAT GAA GGG AAG GCT TCG TCT GCC AAA CAG AGA CTC AAG TGT  
GCC AGT CTC CAA AAA TTT GGA GAA AGA GCT TTC AAA GCA TGG  
GCG GTG GCT CGC CTG AGC CAG AGA TTT CCC AAA GCT GAG TTT  
GCA GAA GTT TCC AAG TTA GTG ACA GAT CTT ACC AAA GTC CAC  
ACG GAA TGC TGC CAT GGA GAT CTG CTT GAA TGT GCT GAT GAC  
AGG GCG GAC CTT GCC AAG TAT ATC TGT GAA AAT CAA GAT TCG  
ATC TCC AGT AAA CTG AAG GAA TGC TGT GAA AAA CCT CTG TTG  
GAA AAA TCC CAC TGC ATT GCC GAA GTG GAA AAT GAT GAG ATG  
CCT GCT GAC TTG CCT TCA TTA GCT GCT GAT TTT GTT GAA AGT  
AAG GAT GTT TGC AAA AAC TAT GCT GAG GCA AAG GAT GTC TTC  
CTG GGC ATG TTT TTG TAT GAA TAT GCA AGA AGG CAT CCT GAT  
TAC TCT GTC GTG CTG CTG CTG AGA CTT GCC AAG ACA TAT GAA  
ACC ACT CTA GAG AAG TGC TGT GCC GCT GCA GAT CCT CAT GAA  
TGC TAT GCC AAA GTG TTC GAT GAA TTT AAA CCT CCT GTG GAA  
GAG CCT CAG AAT TTA ATC AAA CAA AAT TGT GAG CTT TTT GAG  
CAG CTT GGA GAG TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT  
TAC ACC AAG AAA GTA CCC CAA GTG TCA ACT CCA ACT CTT GTA  
GAG GTC TCA AGA AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT  
AAA CAT CCT GAA GCA AAA AGA ATG CCC TGT GCA GAA GAC TAT  
CTA TCC GTG GTC CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA  
ACG CCA GTA AGT GAC AGA GTC ACC AAA TGC TGC ACA GAA TCC  
TTG GTG AAC AGG CGA CCA TGC TTT TCA GCT CTG GAA GTC GAT  
GAA ACA TAC GTT CCC AAA GAG TTT AAT GCT GAA ACA TTC ACC  
TTC CAT GCA GAT ATA TGC ACA CTT TCT GAG AAG GAG AGA CAA  
ATC AAG AAA CAA ACT GCA CTT GTT GAG CTC GTG AAA CAC AAG  
CCC AAG GCA ACA AAA GAG CAA CTG AAA GCT GTT ATG GAT GAT

TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG  
GAG ACC TGC TTT GCC GAG GAG GGT AAA AAA CTT GTT GCT GCA  
AGT CAA GCT GCC TTA GGC TTA TAA

wherein the 5' to 3' strand, beginning with the amino  
terminus is shown, and wherein the abbreviations are  
defined as in claim 4.

8. A human prepro-serum albumin gene as claimed in claim 7  
comprised in the following deoxyribonucleotide sequence:  
5'

TCTCTTCTGTCAACCCACGCCTTTGGCACA ATG AAG TGG GTA  
ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC TCG GCT TAT TCC  
AGG GGT GTG TTT CGT CGA GAT GCA CAC AAG AGT GAG GTT GCT  
CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT TTC AAA GCC TTG  
GTG TTG ATT GCC TTT GCT CAG TAT CTT CAG CAG TGT CCA TTT  
GAA GAT CAT GTA AAA TTA GTC AAT GAA GTA ACT GAA TTT GCA  
AAA ACA TGT GTT GCT GAT GAG TCA GCT GAA AAT TGT GAC AAA  
TCA CTT CAT ACC CTT TTT GGA GAC AAA TTA TGC ACA GTT GCA  
ACT CTT CGT GAA ACC TAT GGT GAA ATG GCT GAC TGC TGT GCA  
AAA CAA GAA CCT GAG AGA AAT GAA TGC TTC TTG CAA CAC AAA  
GAT GAC AAC CCA AAC CTC CCC CGA TTG GTG AGA CCA GAG GTT  
GAT GTG ATG TGC ACT GCT TTT CAT GAC AAT GAA GAG ACA TTT  
TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA AGA CAT CCT TAC  
TTT TAT GCC CCG GAA CTC CTT TTC TTT GCT AAA AGG TAT AAA  
GCT GCT TTT ACA GAA TGT TGC CAA GCT GCT GAT AAA GCT GCC  
TGC CTG TTG CCA AAG CTC GAT GAA CTT CGG GAT GAA GGG AAG  
GCT TCG TCT GCC AAA CAG AGA CTC AAG TGT GCC AGT CTC CAA  
AAA TTT GGA GAA AGA GCT TTC AAA GCA TGG GCG GTG GCT CGC  
CTG AGC CAG AGA TTT CCC AAA GCT GAG TTT GCA GAA GTT TCC  
AAG TTA GTG ACA GAT CTT ACC AAA GTC CAC ACG GAA TGC TGC  
CAT GGA GAT CTG CTT GAA TGT GCT GAT GAC AGG GCG GAC CTT  
GCC AAG TAT ATC TGT GAA AAT CAA GAT TCG ATC TCC AGT AAA  
CTG AAG GAA TGC TGT GAA AAA CCT CTG TTG GAA AAA TCC CAC  
TGC ATT GCC GAA GTG GAA AAT GAT GAG ATG CCT GCT GAC TTG  
CCT TCA TTA GCT GCT GAT TTT GTT GAA AGT AAG GAT GTT TGC  
AAA AAC TAT GCT GAG GCA AAG GAT GTC TTC CTG GGC ATG TTT

TTG TAT GAA TAT GCA AGA AGG CAT CCT GAT TAC TCT GTC GTG  
CTG CTG CTG AGA CTT GCC AAG ACA TAT GAA ACC ACT CTA GAG  
AAG TGC TGT GCC GCT GCA GAT CCT CAT GAA TGC TAT GCC AAA  
GTG TTC GAT GAA TTT AAA CCT CCT GTG GAA GAG CCT CAG AAT  
TTA ATC AAA CAA AAT TGT GAG CTT TTT GAG CAG CTT GGA GAG  
TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT TAC ACC AAG AAA  
GTA CCC CAA GTG TCA ACT CCA ACT CTT GTA GAG GTC TCA AGA  
AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT AAA CAT CCT GAA  
GCA AAA AGA ATG CCC TGT GCA GAA GAC TAT CTA TCC GTG GTC  
CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA ACG CCA GTA AGT  
GAC AGA GTC ACC AAA TGC TGC ACA GAA TCC TTG GTG AAC AGG  
CGA CCA TGC TTT TCA GCT CTG GAA GTC GAT GAA ACA TAC GTT  
CCC AAA GAG TTT AAT GCT GAA ACA TTC ACC TTC CAT GCA GAT  
ATA TGC ACA CTT TCT GAG AAG GAG AGA CAA ATC AAG AAA CAA  
ACT GCA CTT GTT GAG CTC GTG AAA CAC AAG CCC AAG GCA ACA  
AAA GAG CAA CTG AAA GCT GTT ATG GAT GAT TTC GCA GCT TTT  
GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG GAG ACC TGC TTC  
GCC GAG GAG GGT AAA AAA CTT GTT GCT GCA AGT CAA GCT GCC  
TTA GGC TTA TAA CATCTACATTTAAAAGCATCTCAGCCTACCATGAGAATA  
AGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTCGTTGGTG  
TTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAA  
TCTAA

wherein the 5' to 3' strand, beginning with the amino terminus is shown, and wherein the abbreviations are defined as in claim 4.

9. A plasmid having the capability of replication in a prokaryotic or eukaryotic organism, comprising a deoxyribo nucleotide sequence coding for human serum albumin.

10. A plasmid as claimed in claim 8 having the capability of replication in a prokaryotic organism, comprising a human serum albumin or human prepro-serum albumin gene as claimed in any one of claims 1 to 8.

11. A plasmid as claimed in claim 9 or claim 10 having the capability of replication in a prokaryotic organism of the genus Escherichia.
- 5 12. The plasmid of claim 10 designated pGX401 (deposited in E. coli HB101 at the U.S. Dept. of Agriculture Northern Regional Research Center, Peoria, Illinois under accession No. NRRL B-15784) and mutants thereof encoding human serum albumin.
- 10 13. A microorganism transformed by a plasmid as claimed in any one of claims 9 to 12.
14. A microorganism as claimed in claim 13 of the genus Escherichia.
- 15 15. A microorganism as claimed in claim 14 of the species coli.
16. A method of producing prepro-human serum albumin which comprises cultivating on an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and essential minerals and growth factors, under prepro-human serum albumin-producing conditions,  
20 a prokaryotic organism as claimed in claim 13 transformed by a plasmid capable of replicating in said organism and having a deoxyribonucleotide sequence coding for prepro-human serum albumin, and recovering the prepro-human serum albumin so produced.
- 25 17. A method as claimed in claim 16 wherein the prokaryotic organism is E. coli.

- 44 -

18. A method as claimed in claim 17 wherein the prokaryotic organism is transformed by a plasmid substantially similar to plasmid pGX401 as claimed in claim 11.

- 5 19. E. coli strain NRRL No. 15784 (pGX401) or a mutant thereof containing a human prepro-human serum albumin gene.

## CLAIMS FOR THE DESIGNATED STATE: AT

1. A process for preparing a gene coding for human serum albumin (HSA) which comprises obtaining HSA mRNA from HSA-producing cells, in vitro synthesis of complementary DNA (cDNA) using said mRNA as a template and conversion of said cDNA to the double-stranded form.
2. A process as claimed in claim 1 wherein said gene codes for prepro-human serum albumin.
3. A process as claimed in claim 1 wherein said gene comprises the following deoxyribonucleotide sequence which corresponds to the indicated amino acid sequence:

Asp	Ala	His	Lys	Ser	Glu	Val	Ala
G A Y	G C X	C A Y	A A M	Q R S	G A M	G T X	G C X
His	Arg	Phe	Lys	Asp	Leu	Gly	Glu
C A Y	L G N	T T Y	A A M	G A Y	Y T Z	G G X	G A M
Glu	Asn	Phe	Lys	Ala	Leu	Val	Leu
G A M	A A Y	T T Y	A A M	G C X	Y T Z	G T X	Y T Z
Ile	Ala	Phe	Ala	Gln	Tyr	Leu	Gln
A T H	G C X	T T Y	G C X	C A M	T A Y	Y T Z	C A M
Gln	Cys	Pro	Phe	Glu	Asp	His	Val
C A M	T G Y	C C X	T T Y	G A M	G A Y	C A Y	G T X
Lys	Leu	Val	Asn	Glu	Val	Thr	Glu
A A M	Y T Z	G T X	A A Y	G A M	G T X	A C X	G A M
Phe	Ala	Lys	Thr	Cys	Val	Ala	Asp
T T Y	G C X	A A M	A C X	T G Y	G T X	G C X	G A Y
Glu	Ser	Ala	Glu	Asn	Cys	Asp	Lys
G A M	Q R S	G C X	G A M	A A Y	T G Y	G A Y	A A M
Ser	Leu	His	Thr	Leu	Phe	Gly	Asp
Q R S	Y T Z	C A Y	A C X	Y T Z	T T Y	G G X	G A Y
Lys	Leu	Cys	Thr	Val	Ala	Thr	Leu
A A M	Y T Z	T G Y	A C X	G T X	G C X	A C X	Y T Z
Arg	Glu	Thr	Tyr	Gly	Glu	Met	Ala
L G N	G A M	A C X	T A Y	G G X	G A M	A T G	G C X
Asp	Cys	Cys	Ala	Lys	Gln	Glu	Pro
G A Y	T G Y	T G Y	G C X	A A M	C A M	G A M	C C X

Glu G A M	Arg L G N	Asn A A Y	Glu G A M	Cys T G Y	Phe T T Y	Leu Y T Z	Gln C A M
His C A Y	Lys A A M	Asp G A Y	Asp G A Y	Asn A A Y	Pro C C X	Asn A A Y	Leu Y T Z
Pro C C X	Arg L G N	Leu Y T Z	Val G T X	Arg L G N	Pro C C X	Glu G A M	Val G T X
Asp G A Y	Val G T X	Met A T G	Cys T G Y	Thr A C X	Ala G C X	Phe T T Y	His C A Y
Asp G A Y	Asn A A Y	Glu G A M	Glu G A M	Thr A C X	Phe T T Y	Leu Y T Z	Lys A A M
Lys A A M	Tyr T A Y	Leu Y T Z	Tyr T A Y	Glu G A M	Ile A T H	Ala G C X	Arg L G N
Arg L G N	His C A Y	Pro C C X	Tyr T A Y	Phe T T Y	Thr A C X	Ala G C X	Pro C C X
Glu G A M	Leu Y T Z	Leu Y T Z	Phe T T Y	Phe T T Y	Ala G C X	Lys A A M	Arg L G N
Tyr T A Y	Lys A A M	Ala G C X	Ala G C X	Phe T T Y	Thr A C X	Glu G A M	Cys T G Y
Cys T G Y	Ala G C X	Gln C A M	Ala G C X	Asp G A Y	Lys A A M	Ala G C X	Ala G C X
Cys T G Y	Leu Y T Z	Phe T T Y	Pro C C X	Lys A A M	Leu Y T Z	Asp G A Y	Glu G A M
Leu Y T Z	Arg L G N	Asp G A Y	Glu G A M	Gly G G X	Lys A A M	Ala G C X	Ser Q R S
Ser Q R S	Ala G C X	Lys A A M	Gln C A M	Arg L G N	Leu Y T Z	Lys A A M	Cys T G Y
Ala G C X	Ser Q R S	Leu Y T Z	Gln C A M	Lys A A M	Phe T T Y	Gly G G X	Glu G A M
Arg L G N	Ala G C X	Phe T T Y	Lys A A M	Ala G C X	Trp T G G	Ala G C X	Val G T X
Ala G C X	Arg L G N	Leu Y T Z	Ser Q R S	Gln C A M	Arg L G N	Phe T T Y	Pro C C X
Lys A A M	Ala G C X	Glu G A M	Phe T T Y	Ala G C X	Glu G A M	Val G T X	Ser Q R S
Lys A A M	Phe T T Y	Val G T X	Thr A C X	Asp G A Y	Leu Y T Z	Thr A C X	Lys A A M
Val G T X	His C A Y	Thr A C X	Glu G A M	Cys T G Y	Cys T G Y	His C A Y	Gly G G X

Asp G A Y	Leu Y T Z	Leu Y T Z	Glu G A M	Cys T G Y	Ala G C X	Asp G A Y	Asp G A Y
Arg L G N	Ala G C X	Asp G A Y	Leu Y T Z	Ala G C X	Lys A A M	Tyr T A Y	Ile A T H
Cys T G Y	Glu G A M	Asn A A Y	Gln C A M	Asp G A Y	Ser Q R S	Ile A T H	Ser Q R S
Ser Q R S	Lys A A M	Leu Y T Z	Lys A A M	Glu G A M	Cys T G Y	Cys T G Y	Glu G A M
Lys A A M	Pro C C X	Leu Y T Z	Phe T T Y	Glu G A M	Lys A A M	Ser Q R S	His C A Y
Cys T G Y	Ile A T H	Ala G C X	Glu G A M	Val G T X	Glu G A M	Asn A A Y	Asp G A Y
Glu G A M	Met A T G	Pro C C X	Ala G C X	Asp G A Y	Phe T T Y	Pro C C X	Ser Q R S
Phe T T Y	Ala G C X	Val G T X	Asp G A Y	Phe T T Y	Val G T X	Glu G A M	Ser Q R S
Lys A A M	Asp G A Y	Val G T X	Cys T G Y	Lys A A M	Asn A A Y	Tyr T A Y	Ala G C X
Glu G A M	Ala G C X	Lys A A M	Asp G A Y	Val G T X	Phe T T Y	Leu Y T Z	Gly G G X
Met A T G	Phe T T Y	Phe T T Y	Tyr T A Y	Glu G A M	Tyr T A Y	Ala G C X	Arg L G N
Arg L G N	His C A Y	Pro C C X	Asp G A Y	Tyr T A Y	Ser Q R S	Val G T X	Val G T X
Leu Y T Z	Leu Y T Z	Leu Y T Z	Arg L G N	Leu Y T Z	Ala G C X	Lys A A M	Thr A C X
Tyr T A Y	Glu G A M	Thr A C X	Thr A C X	Leu Y T Z	Glu G A M	Lys A A M	Cys T G Y
Cys T G Y	Ala G C X	Ala G C X	Ala G C X	Asp G A Y	Pro C C X	His C A Y	Glu G A M
Cys T G Y	Tyr T A Y	Ala G C X	Lys A A M	Val G T X	Phe T T Y	Asp G A Y	Glu G A M
Phe T T Y	Lys A A M	Pro C C X	Pro C C X	Val G T X	Glu G A M	Glu G A M	Pro C C X



0206733

4

Gln C A M	Asn A A Y	Phe T T Y	Ile <sup>4</sup> A T H	Lys A A M	Gln C A M	Asn A A Y	Cys T G Y
Glu G A M	Leu Y T Z	Phe T T Y	Glu G A M	Gln C A M	Leu Y T Z	Gly G G X	Glu G A M
Tyr T A Y	Lys A A M	Phe T T Y	Gln C A M	Asn A A Y	Ala G C X	Leu Y T Z	Phe T T Y
Val G T X	Arg L G N	Tyr T A Y	Thr A C X	Lys A A M	Lys A A M	Val G T X	Pro C C X
Gln C A M	Leu Y T Z	Ser Q R S	Thr A C X	Pro C C X	Thr A C X	Leu Y T Z	Val G T X
Glu G A M	Val G T X	Ser Q R S	Arg L G N	Asn A A Y	Leu Y T Z	Gly G G X	Lys A A M
Val G T X	Gly G G X	Ser Q R S	Lys A A M	Cys T G Y	Cys T G Y	Lys A A M	His C A Y
Pro C C X	Glu G A M	Ala G C X	Lys A A M	Arg L G N	Met A T G	Pro C C X	Cys T G Y
Ala G C X	Glu G A M	Asp G A Y	Tyr T A Y	Leu Y T Z	Ser Q R S	Val G T X	Val G T X
Leu Y T Z	Asn A A Y	Gln C A M	Leu Y T Z	Cys T G Y	Val G T X	Leu Y T Z	His C A Y
Glu G A M	Lys A A M	Thr A C X	Pro C C X	Val G T X	Ser Q R S	Asp G A Y	Arg L G N
Val G T X	Thr A C X	Lys A A M	Cys T G Y	Cys T G Y	Thr A C X	Glu G A M	Ser Q R S
Leu Y T Z	Val G T X	Asn A A Y	Arg L G N	Arg L G N	Pro C C X	Gly G G X	Phe T T Y
Ser Q R S	Ala G C X	Leu Y T Z	Glu G A M	Val G T X	Asp G A Y	Glu G A M	Thr A C X
Tyr T A Y	Val G T X	Pro C C X	Lys A A M	Glu G A M	Phe T T Y	Asn A A Y	Ala G C X
Glu G A M	Thr A C X	Phe T T Y	Thr A C X	Phe T T Y	His C A Y	Ala G C X	Asp G A Y
Ile A T H	Cys T G Y	Thr A C X	Leu Y T Z	Ser Q R S	Glu G A M	Lys A A M	Glu G A M

Arg	Gln	Ile	Lys	Lys	Glu	Thr	Ala
L G N	C A M	A T H	A A M	A A M	G A M	A C X	G C X
Leu	Val	Glu	Leu	Val	Lys	His	Lys
Y T Z	G T X	G A M	Y T Z	G T X	A A M	C A Y	A A M
Pro	Lys	Ala	Thr	Lys	Glu	Glu	Leu
C C X	A A M	G C X	A C X	A A M	G A M	G A M	Y T Z
Lys	Ala	Val	Met	Asp	Asp	Phe	Ala
A A M	G C X	G T X	A T G	G A Y	G A Y	T T Y	G C X
Ala	Phe	Val	Glu	Lys	Cys	Cys	Lys
G C X	T T Y	G T X	G A M	A A M	T G Y	T G Y	A A M
Ala	Asp	Asp	Lys	Glu	Thr	Cys	Phe
G C X	G A Y	G A Y	A A M	G A M	A C X	T G Y	T T Y
Ala	Glu	Glu	Gly	Lys	Lys	Leu	Val
G C X	G A M	G A M	G G X	A A M	A A M	Y T Z	G T X
Ala	Ala	Ser	Glu	Ala	Val	Leu	Gly
G C X	G C X	Q R S	G A M	G C X	G T X	Y T Z	G G X
Leu							
Y T Z	T A A						

wherein, the 5' to 3' strand, beginning with the amino terminus and the amino acids for which each triplet codes are shown, and wherein the abbreviations have the following standard meanings:

A is deoxyadenyl

T is thymidyl

G is deoxyguanyl

C is deoxycytosyl

X is A, T, C or G

Y is T or C

When Y is C, Z is A, T, C or G

When Y is T, Z is A or G

H is A, T or C

Q is T or A

When Q is T, R is C and S is A, T, C or G

When Q is A, R is G and S is T or C

6

M is A or G  
 L is A or C  
 When L is A, N is A or G  
 When L is C, N is A, T, C or G  
 GLY is glycine  
 ALA is alanine  
 VAL is valine  
 LEU is leucine  
 ILE is isoleucine  
 SER is serine  
 THR is threonine  
 PHE is phenylalanine  
 TYR is tyrosine  
 TRP is tryptophan  
 CYS is cysteine  
 MET is methionine  
 ASP is aspartic acid  
 GLU is glutamic acid  
 LYS is lysine  
 ARG is arginine  
 HIS is histidine  
 PRO is proline  
 GLN is glutamine  
 ASN is asparagine

4. A process as claimed in claim 2 wherein said gene comprises the following deoxyribonucleotide sequence:

Met	Lys	Trp	Val	Thr	Phe	
A T G	A A M	T G G	G T X	A C X	T T Y	
Ile	Ser	Leu	Leu	Phe	Leu	Phe
A T H	Q R S	Y T Z	Y T Z	T T Y	Y T Z	T T Y
Ser	Ser	Ala	Tyr	Ser	Arg	Gly
Q R S	Q R S	G C X	T A Y	Q R S	L G N	G G X
Val	Phe	Arg	Arg	Asp	Ala	His
G T X	T T Y	L G N	L G N	G A Y	G C X	C A Y
						Lys
						A A M

Ser	Glu	Val	Ala	His	Arg	Phe	Lys
Q R S	G A M	G T X	G C X	C A Y	L G N	T T Y	A A M
Asp	Leu	Gly	Glu	Glu	Asn	Phe	Lys
G A Y	Y T Z	G G X	G A M	G A M	A A Y	T T Y	A A M
Ala	Leu	Val	Leu	Ile	Ala	Phe	Ala
G C X	Y T Z	G T X	Y T Z	A T H	G C X	T T Y	G C X
Gln	Tyr	Leu	Gln	Gln	Cys	Pro	Phe
C A M	T A Y	Y T Z	C A M	C A M	T G Y	C C X	T T Y
Glu	Asp	His	Val	Lys	Leu	Val	Asn
G A M	G A Y	C A Y	G T X	A A M	Y T Z	G T X	A A Y
Glu	Val	Thr	Glu	Phe	Ala	Lys	Thr
G A M	G T X	A C X	G A M	T T Y	G C X	A A M	A C X
Cys	Val	Ala	Asp	Glu	Ser	Ala	Glu
T G Y	G T X	G C X	G A Y	G A M	Q R S	G C X	G A M
Asn	Cys	Asp	Lys	Ser	Leu	His	Thr
A A Y	T G Y	G A Y	A A M	Q R S	Y T Z	C A Y	A C X
Leu	Phe	Gly	Asp	Lys	Leu	Cys	Thr
Y T Z	T T Y	G G X	G A Y	A A M	Y T Z	T G Y	A C X
Val	Ala	Thr	Leu	Arg	Glu	Thr	Tyr
G T X	G C X	A C X	Y T Z	L G N	G A M	A C X	T A Y
Gly	Glu	Met	Ala	Asp	Cys	Cys	Ala
G G X	G A M	A T G	G C X	G A Y	T G Y	T G Y	G C X
Lys	Gln	Glu	Pro	Glu	Arg	Asn	Glu
A A M	C A M	G A M	C C X	G A M	L G N	A A Y	G A M
Cys	Phe	Leu	Gln	His	Lys	Asp	Asp
T G Y	T T Y	Y T Z	C A M	C A Y	A A M	G A Y	G A Y
Asn	Pro	Asn	Leu	Pro	Arg	Leu	Val
A A Y	C C X	A A Y	Y T Z	C C X	L G N	Y T Z	G T X
Arg	Pro	Glu	Val	Asp	Val	Met	Cys
L G N	C C X	G A M	G T X	G A Y	G T X	A T G	T G Y
Thr	Ala	Phe	His	Asp	Asn	Glu	Glu
A C X	G C X	T T Y	C A Y	G A Y	A A Y	G A M	G A M
Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr
A C X	T T Y	Y T Z	A A M	A A M	T A Y	Y T Z	T A Y

Glu	Ile	Ala	Arg	Arg	His	Pro	Tyr
G A M	A T H	G C X	L G N	L G N	C A Y	C C X	T A Y
Phe	Thr	Ala	Pro	Glu	Leu	Leu	Phe
T T Y	A C X	G C X	C C X	G A M	Y T Z	Y T Z	T T Y
Phe	Ala	Lys	Arg	Tyr	Lys	Ala	Ala
T T Y	G C X	A A M	L G N	T A Y	A A M	G C X	G C X
Phe	Thr	Glu	Cys	Cys	Ala	Gln	Ala
T T Y	A C X	G A M	T G Y	T G Y	G C X	C A M	G C X
Asp	Lys	Ala	Ala	Cys	Leu	Phe	Pro
G A Y	A A M	G C X	G C X	T G Y	Y T Z	T T Y	C C X
Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu
A A M	Y T Z	G A Y	G A M	Y T Z	L G N	G A Y	G A M
Gly	Lys	Ala	Ser	Ser	Ala	Lys	Gln
G G X	A A M	G C X	Q R S	Q R S	G C X	A A M	C A M
Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln
L G N	Y T Z	A A M	T G Y	G C X	Q R S	Y T Z	C A M
Lys	Phe	Gly	Glu	Arg	Ala	Phe	Lys
A A M	T T Y	G G X	G A M	L G N	G C X	T T Y	A A M
Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser
G C X	T G G	G C X	G T X	G C X	L G N	Y T Z	Q R S
Gln	Arg	Phe	Pro	Lys	Ala	Glu	Phe
C A M	L G N	T T Y	C C X	A A M	G C X	G A M	T T Y
Ala	Glu	Val	Ser	Lys	Phe	Val	Thr
G C X	G A M	G T X	Q R S	A A M	T T Y	G T X	A C X
Asp	Leu	Thr	Lys	Val	His	Thr	Glu
G A Y	Y T Z	A C X	A A M	G T X	C A Y	A C X	G A M
Cys	Cys	His	Gly	Asp	Leu	Leu	Glu
T G Y	T G Y	C A Y	G G X	G A Y	Y T Z	Y T Z	G A M
Cys	Ala	Asp	Asp	Arg	Ala	Asp	Leu
T G Y	G C X	G A Y	G A Y	L G N	G C X	G A Y	Y T Z
Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln
G C X	A A M	T A Y	A T H	T G Y	G A M	A A Y	C A M
Asp	Ser	Ile	Ser	Ser	Lys	Leu	Lys
G A Y	Q R S	A T H	Q R S	Q R S	A A M	Y T Z	A A M

Glu G A M	Cys T G Y	Cys T G Y	Glu G A M	Lys A A M	Pro C C X	Leu Y T Z	Phe T T Y
Glu G A M	Lys A A M	Ser Q R S	His C A Y	Cys T G Y	Ile A T H	Ala G C X	Glu G A M
Val G T X	Glu G A M	Asn A A Y	Asp G A Y	Glu G A M	Met A T G	Pro C C X	Ala G C X
Asp G A Y	Phe T T Y	Pro C C X	Ser Q R S	Phe T T Y	Ala G C X	Val G T X	Asp G A Y
Phe T T Y	Val G T X	Glu G A M	Ser Q R S	Lys A A M	Asp G A Y	Val G T X	Cys T G Y
Lys A A M	Asn A A Y	Tyr T A Y	Ala G C X	Glu G A M	Ala G C X	Lys A A M	Asp G A Y
Val G T X	Phe T T Y	Leu Y T Z	Gly G G X	Met A T G	Phe T T Y	Phe T T Y	Tyr T A Y
Glu G A M	Tyr T A Y	Ala G C X	Arg L G N	Arg L G N	His C A Y	Pro C C X	Asp G A Y
Tyr T A Y	Ser Q R S	Val G T X	Val G T X	Leu Y T Z	Leu Y T Z	Leu Y T Z	Arg L G N
Leu Y T Z	Ala G C X	Lys A A M	Thr A C X	Tyr T A Y	Glu G A M	Thr A C X	Thr A C X
Leu Y T Z	Glu G A M	Lys A A M	Cys T G Y	Cys T G Y	Ala G C X	Ala G C X	Ala G C X
Asp G A Y	Pro C C X	His C A Y	Glu G A M	Cys T G Y	Tyr T A Y	Ala G C X	Lys A A M
Val G T X	Phe T T Y	Asp G A Y	Glu G A M	Phe T T Y	Lys A A M	Pro C C X	Pro C C X
Val G T X	Glu G A M	Glu G A M	Pro C C X	Gln C A M	Asn A A Y	Phe T T Y	Ile A T H
Lys A A M	Gln C A M	Asn A A Y	Cys T G Y	Glu G A M	Leu Y T Z	Phe T T Y	Glu G A M
Gln C A M	Leu Y T Z	Gly G G X	Glu G A M	Tyr T A Y	Lys A A M	Phe T T Y	Gln C A M
Asn A A Y	Ala G C X	Leu Y T Z	Phe T T Y	Val G T X	Arg L G N	Tyr T A Y	Thr A C X

Lys A A M	Lys A A M	Val G T X	Pro C C X	Gln C A M	Leu Y T Z	Ser Q R S	Thr A C X
Pro C C X	Thr A C X	Leu Y T Z	Val G T X	Glu G A M	Val G T X	Ser Q R S	Arg L G N
Asn A A Y	Leu Y T Z	Gly G G X	Lys A A M	Val G T X	Gly G G X	Ser Q R S	Lys A A M
Cys T G Y	Cys T G Y	Lys A A M	His C A Y	Pro C C X	Glu G A M	Ala G C X	Lys A A M
Arg L G N	Met A T G	Pro C C X	Cys T G Y	Ala G C X	Glu G A M	Asp G A Y	Tyr T A Y
Leu Y T Z	Ser Q R S	Val G T X	Val G T X	Leu Y T Z	Asn A A Y	Gln C A M	Leu Y T Z
Cys T G Y	Val G T X	Leu Y T Z	His C A Y	Glu G A M	Lys A A M	Thr A C X	Pro C C X
Val G T X	Ser Q R S	Asp G A Y	Arg L G N	Val G T X	Thr A C X	Lys A A M	Cys T G Y
Cys T G Y	Thr A C X	Glu G A M	Ser Q R S	Leu Y T Z	Val G T X	Asn A A Y	Arg L G N
Arg L G N	Pro C C X	Gly G G X	Phe T T Y	Ser Q R S	Ala G C X	Leu Y T Z	Glu G A M
Val G T X	Asp G A Y	Glu G A M	Thr A C X	Tyr T A Y	Val G T X	Pro C C X	Lys A A M
Glu G A M	Phe T T Y	Asn A A Y	Ala G C X	Glu G A M	Thr A C X	Phe T T Y	Thr A C X
Phe T T Y	His C A Y	Ala G C X	Asp G A Y	Ile A T H	Cys T G Y	Thr A C X	Leu Y T Z
Ser Q R S	Glu G A M	Lys A A M	Glu G A M	Arg L G N	Gln C A M	Ile A T H	Lys A A M
Lys A A M	Glu G A M	Thr A C X	Ala G C X	Leu Y T Z	Val G T X	Glu G A M	Leu Y T Z
Val G T X	Lys A A M	His C A Y	Lys A A M	Pro C C X	Lys A A M	Ala G C X	Thr A C X
Lys A A M	Glu G A M	Glu G A M	Leu Y T Z	Lys A A M	Ala G C X	Val G T X	Met A T G
Asp G A Y	Asp G A Y	Phe T T Y	Ala G C X	Ala G C X	Phe T T Y	Val G T X	Glu G A M

11

Lys	Cys	Cys	Lys	Ala	Asp	Asp	Lys
A A M	T G Y	T G Y	A A M	G C X	G A Y	G A Y	A A M
Glu	Thr	Cys	Phe	Ala	Glu	Glu	Gly
G A M	A C X	T G Y	T T Y	G C X	G A M	G A M	G G X
Lys	Lys	Leu	Val	Ala	Ala	Ser	Glu
A A M	A A M	Y T Z	G T X	G C X	G C X	Q R S	G A M
Ala	Val	Leu	Gly	Leu			
G C X	G T X	Y T Z	G G X	Y T Z	T A A		

wherein the 5' and 3' strand, beginning with the amino terminus, and the amino acids for which each triplet codes are shown, and wherein the abbreviations are defined as in claim 3.

5. A process as claimed in claim 3 wherein said gene comprises the following deoxyribonucleotide sequence:

GAT GCA CAC AAG AGT GAG GTT GCT CAT CGG TTT AAA GAT TTG  
 GGA GAA GAA AAT TTC AAA GCC TTG GTG TTG ATT GCC TTT GCT  
 CAG TAT CTT CAG CAG TGT CCA TTT GAA GAT CAT GTA AAA TTA  
 GTG AAT GAA GTA ACT GAA TTT GCA AAA ACA TGT GTT GCT GAT  
 GAG TCA GCT GAA AAT TGT GAC AAA TCA CTT CAT ACC CTT TTT  
 GGA GAC AAA TTA TGC ACA GTT GCA ACT CTT CGT GAA ACC TAT  
 GGT GAA ATG GCT GAC TGC TGT GCA AAA CAA GAA CCT GAG AGA  
 AAT GAA TGC TTC TTG CAA CAC AAA GAT GAC AAC CCA AAC CTC  
 CCC CGA TTG GTG AGA CCA GAG GTT GAT GTG ATG TGC ACT GCT  
 TTT CAT GAC AAT GAA GAG ACA TTT TTG AAA AAA TAC TTA TAT  
 GAA ATT GCC AGA AGA CAT CCT TAC TTT TAT GCC CCG GAA CTC  
 CTT TTC TTT GCT AAA AGG TAT AAA GCT GCT TTT ACA GAA TGT  
 TGC CAA GCT GCT GAT AAA GCT GCC TGC CTG TTG CCA AAG CTC  
 GAT GAA CTT CGG GAT GAA GGG AAG GCT TCG TCT GCC AAA CAG  
 AGA CTC AAG TGT GCC AGT CTC CAA AAA TTT GGA GAA AGA GCT  
 TTC AAA GCA TGG GCG GTG GCT CGC CTG AGC CAG AGA TTT CCC  
 AAA GCT GAG TTT GCA GAA GTT TCC AAG TTA GTG ACA GAT CTT  
 ACC AAA GTC CAC ACG GAA TGC TGC CAT GGA GAT CTG CTT GAA  
 TGT GCT GAT GAC AGG GCG GAC CTT GCC AAG TAT ATC TGT GAA  
 AAT CAA GAT TCG ATC TCC AGT AAA CTG AAG GAA TGC TGT GAA



AAA CCT CTG TTG GAA AAA TCC CAC TGC ATT GCC GAA GTG GAA  
AAT GAT GAG ATG CCT GCT GAC TTG CCT TCA TTA GCT GCT GAT  
TTT GTT GAA AGT AAG GAT GTT TGC AAA AAC TAT GCT GAG GCA  
AAG GAT GTC TTC CTG GGC ATG TTT TTG TAT GAA TAT GCA AGA  
AGG CAT CCT GAT TAC TCT GTC GTG CTG CTG CTG AGA CTT GCC  
AAG ACA TAT GAA ACC ACT CTA GAG AAG TGC TGT GCC GCT GCA  
GAT CCT CAT GAA TGC TAT GCC AAA GTG TTC GAT GAA TTT AAA  
CCT CCT GTG GAA GAG CCT CAG AAT TTA ATC AAA CAA AAT TGT  
GAG CTT TTT GAG CAG CTT GGA GAG TAC AAA TTC CAG AAT GCG  
CTA TTA GTT CGT TAC ACC AAG AAA GTA CCC CAA GTG TCA ACT  
CCA ACT CTT GTA GAG GTC TCA AGA AAC CTA GGA AAA GTG GGC  
AGC AAA TGT TGT AAA CAT CCT GAA GCA AAA AGA ATG CCC TGT  
GCA GAA GAC TAT CTA TCC GTG GTC CTG AAC CAG TTA TGT GTG  
TTG CAT GAG AAA ACG CCA GTA AGT GAC AGA GTC ACC AAA TGC  
TGC ACA GAA TCC TTG GTG AAC AGG CGA CCA TGC TTT TCA GCT  
CTG GAA GTC GAT GAA ACA TAC GTT CCC AAA GAG TTT AAT GCT  
GAA ACA TTC ACC TTC CAT GCA GAT ATA TGC ACA CTT TCT GAG  
AAG GAG AGA CAA ATC AAG AAA CAA ACT GCA CTT GTT GAG CTC  
GTG AAA CAC AAG CCC AAG GCA ACA AAA GAG CAA CTG AAA GCT  
GTT ATG GAT GAT TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG  
GCT GAC GAT AAG GAG ACC TGC TTT GCC GAG GAG GGT AAA AAA  
CTT GTT GCT GCA AGT CAA GCT GCC TTA GGC TTA TAA

wherein the 5' to 3' strand, beginning with the amino terminus is shown, and wherein the abbreviations are defined as in claim 3.

6. A process as claimed in claim 4 wherein said gene comprises the following deoxyribonucleotide sequence:

ATG AAG TGG GTA ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC  
TCG GCT TAT TCC AGG GGT GTG TTT CGT CGA GAT GCA CAC AAG  
AGT GAG GTT GCT CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT  
TTC AAA GCC TTG GTG TTG ATT GCC TTT GCT CAG TAT CTT CAG  
CAG TGT CCA TTT GAA GAT CAT GTA AAA TTA GTG AAT GAA GTA  
ACT GAA TTT GCA AAA ACA TGT GTT GCT GAT GAG TCA GCT GAA

AAT TGT GAC AAA TCA CTT CAT ACC CTT TTT GGA GAC AAA TTA  
TGC ACA GTT GCA ACT CTT CGT GAA ACC TAT GGT GAA ATG GCT  
GAC TGC TGT GCA AAA CAA GAA CCT GAG AGA AAT GAA TGC TTC  
TTG CAA CAC AAA GAT GAC AAC CCA AAC CTC CCC CGA TTG GTG  
AGA CCA GAG GTT GAT GTG ATG TGC ACT GCT TTT CAT GAC AAT  
GAA GAG ACA TTT TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA  
AGA CAT CCT TAC TTT TAT GCC CCG GAA CTC CTT TTC TTT GCT  
AAA AGG TAT AAA GCT GCT TTT ACA GAA TGT TGC CAA GCT GCT  
GAT AAA GCT GCC TGC CTG TTG CCA AAG CTC GAT GAA CTT CGG  
GAT GAA GGG AAG GCT TCG TCT GCC AAA CAG AGA CTC AAG TGT  
GCC AGT CTC CAA AAA TTT GGA GAA AGA GCT TTC AAA GCA TGG  
GCG GTG GCT CGC CTG AGC CAG AGA TTT CCC AAA GCT GAG TTT  
GCA GAA GTT TCC AAG TTA GTG ACA GAT CTT ACC AAA GTC CAC  
ACG GAA TGC TGC CAT GGA GAT CTG CTT GAA TGT GCT GAT GAC  
AGG GCG GAC CTT GCC AAG TAT ATC TGT GAA AAT CAA GAT TCG  
ATC TCC AGT AAA CTG AAG GAA TGC TGT GAA AAA CCT CTG TTG  
GAA AAA TCC CAC TGC ATT GCC GAA GTG GAA AAT GAT GAG ATG  
CCT GCT GAC TTG CCT TCA TTA GCT GCT GAT TTT GTT GAA AGT  
AAG GAT GTT TGC AAA AAC TAT GCT GAG GCA AAG GAT GTC TTC  
CTG GGC ATG TTT TTG TAT GAA TAT GCA AGA AGG CAT CCT GAT  
TAC TCT GTC GTG CTG CTG CTG AGA CTT GCC AAG ACA TAT GAA  
ACC ACT CTA GAG AAG TGC TGT GCC GCT GCA GAT CCT CAT GAA  
TGC TAT GCC AAA GTG TTC GAT GAA TTT AAA CCT CCT GTG GAA  
GAG CCT CAG AAT TTA ATC AAA CAA AAT TGT GAG CTT TTT GAG  
CAG CTT GGA GAG TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT  
TAC ACC AAG AAA GTA CCC GAA GTG TCA ACT CCA ACT CTT GCA  
GAG GTC TCA AGA AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT  
AAA CAT CCT GAA GCA AAA AGA ATG CCC TGT GCA GAA GAC TAT  
CTA TCC GTG GTC CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA  
ACG CCA GTA AGT GAC AGA GTC ACC AAA TGC TGC ACA GAA TCC  
TTG GTG AAC AGG CGA CCA TGC TTT TCA GCT CTG GAA GTC GAT  
GAA ACA TAC GTT CCC AAA GAG TTT AAT GCT GAA ACA TTC ACC  
TTC CAT GCA GAT ATA TGC ACA CTT TCT GAG AAG GAG AGA CAA  
ATC AAG AAA CAA ACT GCA CTT GTT GAG CTC GTG AAA CAC AAG  
CCC AAG GCA ACA AAA GAG CAA CTG AAA GCT GTT ATG GAT GAT

TTC GCA GCT TTT GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG  
GAG ACC TGC TTT GCC GAG GAG GGT AAA AAA CTT GTT GCT GCA  
AGT CAA GCT GCC TTA GGC TTA TAA

wherein the 5' to 3' strand, beginning with the amino  
terminus is shown, and wherein the abbreviations are  
defined as in claim 3.

7. A process as claimed in claim 6 wherein said  
gene is comprised in the following deoxyribonucleotide  
sequence:

5'

TCTCTTCTGTCAACCCACGCCCTTTGGCACA ATG AAG TGG GTA  
ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC TCG GCT TAT TCC  
AGG GGT GTG TTT CGT CGA GAT GCA CAC AAG AGT GAG GTT GCT  
CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT TTC AAA GCC TTG  
GTG TTG ATT GCC TTT GCT CAG TAT CTT CAG CAG TGT CCA TTT  
GAA GAT CAT GTA AAA TTA GTC AAT GAA GTA ACT GAA TTT GCA  
AAA ACA TGT GTT GCT GAT GAG TCA GCT GAA AAT TGT GAC AAA  
TCA CTT CAT ACC CTT TTT GGA GAC AAA TTA TGC ACA GTT GCA  
ACT CTT CGT GAA ACC TAT GGT GAA ATG GCT GAC TGC TGT GCA  
AAA CAA GAA CCT GAG AGA AAT GAA TGC TTC TTG CAA CAC AAA  
GAT GAC AAC CCA AAC CTC CCC CGA TTG GTG AGA CCA GAG GTT  
GAT GTG ATG TGC ACT GCT TTT CAT GAC AAT GAA GAG ACA TTT  
TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA AGA CAT CCT TAC  
TTT TAT GCC CCG GAA CTC CTT TTC TTT GCT AAA AGG TAT AAA  
GCT GCT TTT ACA GAA TGT TGC CAA GCT GCT GAT AAA GCT GCC  
TGC CTG TTG CCA AAG CTC GAT GAA CTT CGG GAT GAA GGG AAG  
GCT TCG TCT GCC AAA CAG AGA CTC AAG TGT GCC AGT CTC CAA  
AAA TTT GGA GAA AGA GCT TTC AAA GCA TGG GCG GTG GCT CGC  
CTG AGC CAG AGA TTT CCC AAA GCT GAG TTT GCA GAA GTT TCC  
AAG TTA GTG ACA GAT CTT ACC AAA GTC CAC ACG GAA TGC TGC  
CAT GGA GAT CTG CTT GAA TGT GCT GAT GAC AGG GCG GAC CTT  
GCC AAG TAT ATC TGT GAA AAT CAA GAT TCG ATC TCC AGT AAA  
CTG AAG GAA TGC TGT GAA AAA CCT CTG TTG GAA AAA TCC CAC  
TGC ATT GCC GAA GTG GAA AAT GAT GAG ATG CCT GCT GAC TTG  
CCT TCA TTA GCT GCT GAT TTT GTT GAA AGT AAG GAT GTT TGC  
AAA AAC TAT GCT GAG GCA AAG GAT GTC TTC CTG GGC ATG TTT

TTG TAT GAA TAT GCA AGA AGG CAT CCT GAT TAC TCT GTC GTG  
CTG CTG CTG AGA CTT GCC AAG ACA TAT GAA ACC ACT CTA GAG  
AAG TGC TGT GCC GCT GCA GAT CCT CAT GAA TGC TAT GCC AAA  
GTG TTC GAT GAA TTT AAA CCT CCT GTG GAA GAG CCT CAG AAT  
TTA ATC AAA CAA AAT TGT GAG CTT TTT GAG CAG CTT GGA GAG  
TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT TAC ACC AAG AAA  
GTA CCC CAA GTG TCA ACT CCA ACT CTT GTA GAG GTC TCA AGA  
AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT AAA CAT CCT GAA  
GCA AAA AGA ATG CCC TGT GCA GAA GAC TAT CTA TCC GTG GTC  
CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA ACG CCA GTA AGT  
GAC AGA GTC ACC AAA TGC TGC ACA GAA TCC TTG GTG AAC AGG  
CGA CCA TGC TTT TCA GCT CTG GAA GTC GAT GAA ACA TAC GTT  
CCC AAA GAG TTT AAT GCT GAA ACA TTC ACC TTC CAT GCA GAT  
ATA TGC ACA CTT TCT GAG AAG GAG AGA CAA ATC AAG AAA CAA  
ACT GCA CTT GTT GAG CTC GTG AAA CAC AAG CCC AAG GCA ACA  
AAA GAG CAA CTG AAA GCT GTT ATG GAT GAT TTC GCA GCT TTT  
GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG GAG ACC TGC TTC  
GCC GAG GAG GGT AAA AAA CTT GTT GCT GCA AGT CAA GCT GCC  
TTA GGC TTA TAA CATCTACATTTAAAGCATCTCAGCCTACCATGAGAATA  
AGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTCGTTGGTG  
TTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAA  
TCTAA

wherein the 5' to 3' strand, beginning with the amino terminus is shown, and wherein the abbreviations are defined as in claim 3.

8. A process for preparing a plasmid encoding human serum albumin which comprises inserting a deoxy-ribonucleotide sequence coding for human serum albumin into a plasmid having the capability of replication in a prokaryotic or eukaryotic organism.

9. A process as claimed in claim 8 wherein the deoxyribonucleotide sequence coding for human serum albumin is prepared by a process as claimed in any one of claims 1 to 7.

16

10. A process as claimed in claim 8 or claim 9 wherein the deoxyribonucleotide sequence coding for human serum albumin is inserted into a plasmid having the capability of replication in a prokaryotic organism of the genus Escherichia.
11. The process of claim 10 wherein the deoxyribonucleotide sequence of claim 8 is inserted at the Pst I site of plasmid pBR322 so as to prepare plasmid pGX401.
12. A process for preparing a microorganism containing a gene coding for human serum albumin which comprises transforming a microorganism with a plasmid capable of replicating in said microorganism and including said gene.
13. A process as claimed in claim 12 wherein said plasmid is prepared by a process as claimed in any one of claims 8 to 11.
14. A microorganism transformed by a plasmid containing a deoxyribonucleotide sequence as defined in any one of claims 3 to 7.
15. A microorganism as claimed in claim 14 of the genus Escherichia.
16. A method of producing prepro-human serum albumin which comprises cultivating on an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and essential minerals and growth factors, under prepro-human serum albumin-producing conditions, a prokaryotic organism transformed by a plasmid capable of replicating in said organism and having a deoxyribonucleotide sequence coding for

17

prepro-human serum albumin, and recovering the prepro-human serum albumin so produced.

17. A method as claimed in claim 16 wherein the prokaryotic organism is E. coli.

5 18. A method as claim in claim 17 wherein the prokaryotic organism is transformed by a plasmid substantially similar to plasmid pGX401.

10 19. E. coli strain NRRL No. 15784 (pGX401), or a mutant thereof containing a human prepro-human serum albumin gene.

FIG. 1.

PARTIAL RESTRICTION MAPS OF HSA cDNA IN pGX401




FIG. 4




Figure 2

Complete Nucleotide Sequence of the  
HSA Insert In Clone pGX401

```

5' TCTCTTCTGTCAACCCACGCCTTTGGCACA ATG AAG TGG GTA
                                     |<-----
                                     Met Lys Trp Val

----- pre HSA ----->|
Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala Tyr Ser
ACC TTT ATT TCC CTT CTT TTT CTC TTT AGC TCG GCT TAT TCC

|<----- pro HSA ----->|
Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala
AGG GGT GTG TTT CGT CGA GAT GCA CAC AAG AGT GAG GTT GCT

His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu
CAT CGG TTT AAA GAT TTG GGA GAA GAA AAT TTC AAA GCC TTG

Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe
GTG TTG ATT GCC TTT GCT CAG TAT CTT CAG CAG TGT CCA TTT

Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala
GAA GAT CAT GTA AAA TTA GTC AAT GAA GTA ACT GAA TTT GCA

Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
AAA ACA TGT GTT GCT GAT GAG TCA GCT GAA AAT TGT GAC AAA

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala
TCA CTT CAT ACC CTT TTT GGA GAC AAA TTA TGC ACA GTT GCA

Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala
ACT CTT CGT GAA ACC TAT GGT GAA ATG GCT GAC TGC TGT GCA

Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln His Lys
AAA CAA GAA CCT GAG AGA AAT GAA TGC TTC TTG CAA CAC AAA

Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val
GAT GAC AAC CCA AAC CTC CCC CGA TTG GTG AGA CCA GAG GTT

Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe
GAT GTG ATG TGC ACT GCT TTT CAT GAC AAT GAA GAG ACA TTT

Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr
TTG AAA AAA TAC TTA TAT GAA ATT GCC AGA AGA CAT CCT TAC

Phe Thr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys
TTT TAT GCC CCG GAA CTC CTT TTC TTT GCT AAA AGG TAT AAA

```



Figure 2 (continued)

Ala	Ala	Phe	Thr	Glu	Cys	Cys	Ala	Gln	Ala	Asp	Lys	Ala	Ala
GCT	GCT	TTT	ACA	GAA	TGT	TGC	CAA	GCT	GCT	GAT	AAA	GCT	GCC
Cys	Leu	Phe	Pro	Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys
TGC	CTG	TTG	CCA	AAG	CTC	GAT	GAA	CTT	CGG	GAT	GAA	GGG	AAG
Ala	Ser	Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln
GCT	TCG	TCT	GCC	AAA	CAG	AGA	CTC	AAG	TGT	GCC	AGT	CTC	CAA
Lys	Phe	Gly	Glu	Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg
AAA	TTT	GGA	GAA	AGA	GCT	TTC	AAA	GCA	TGG	GCG	GTG	GCT	CGC
Leu	Ser	Gln	Arg	Phe	Pro	Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser
CTG	AGC	CAG	AGA	TTT	CCC	AAA	GCT	GAG	TTT	GCA	GAA	GTT	TCC
Lys	Phe	Val	Thr	Asp	Leu	Thr	Lys	Val	His	Thr	Glu	Cys	Cys
AAG	TTA	GTG	ACA	GAT	CTT	ACC	AAA	GTC	CAC	ACG	GAA	TGC	TGC
His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	Arg	Ala	Asp	Leu
CAT	GGA	GAT	CTG	CTT	GAA	TGT	GCT	GAT	GAC	AGG	GCG	GAC	CTT
Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	Ser	Lys
GCC	AAG	TAT	ATC	TGT	GAA	AAT	CAA	GAT	TCG	ATC	TCC	AGT	AAA
Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Phe	Glu	Lys	Ser	His
CTG	AAG	GAA	TGC	TGT	GAA	AAA	CCT	CTG	TTG	GAA	AAA	TCC	CAC
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Phe
TGC	ATT	GCC	GAA	GTG	GAA	AAT	GAT	GAG	ATG	CCT	GCT	GAC	TTG
Pro	Ser	Phe	Ala	Val	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys
CCT	TCA	TTA	GCT	GCT	GAT	TTT	GTT	GAA	AGT	AAG	GAT	GTT	TGC
Lys	Asn	Tyr	Ala	Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe
AAA	AAC	TAT	GCT	GAG	GCA	AAG	GAT	GTC	TTC	CTG	GGC	ATG	TTT
Phe	Tyr	Glu	Tyr	Ala	Arg	Arg	His	Pro	Asp	Tyr	Ser	Val	Val
TTG	TAT	GAA	TAT	GCA	AGA	AGG	CAT	CCT	GAT	TAC	TCT	GTC	GTG
Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	Tyr	Glu	Thr	Thr	Leu	Glu
CTG	CTG	CTG	AGA	CTT	GCC	AAG	ACA	TAT	GAA	ACC	ACT	CTA	GAG
Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	Cys	Tyr	Ala	Lys
AAG	TGC	TGT	GCC	GCT	GCA	GAT	CCT	CAT	GAA	TGC	TAT	GCC	AAA
Val	Phe	Asp	Glu	Phe	Lys	Pro	Pro	Val	Glu	Glu	Pro	Gln	Asn
GTG	TTC	GAT	GAA	TTT	AAA	CCT	CCT	GTG	GAA	GAG	CCT	CAG	AAT
Phe	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu
TTA	ATC	AAA	CAA	AAT	TGT	GAG	CTT	TTT	GAG	CAG	CTT	GGA	GAG

Figure 2 (continued)

Tyr Lys Phe Gln Asn Ala Leu Phe Val Arg Tyr Thr Lys Lys  
 TAC AAA TTC CAG AAT GCG CTA TTA GTT CGT TAC ACC AAG AAA  
 Val Pro Gln Leu Ser Thr Pro Thr Leu Val Glu Val Ser Arg  
 GTA CCC CAA GTG TCA ACT CCA ACT CTT GTA GAG GTC TCA AGA  
 Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu  
 AAC CTA GGA AAA GTG GGC AGC AAA TGT TGT AAA CAT CCT GAA  
 Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val  
 GCA AAA AGA ATG CCC TGT GCA GAA GAC TAT CTA TCC GTG GTC  
 Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser  
 CTG AAC CAG TTA TGT GTG TTG CAT GAG AAA ACG CCA GTA AGT  
 Asp Arg Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg  
 GAC AGA GTC ACC AAA TGC TGC ACA GAA TCC TTG GTG AAC AGG  
 Arg Pro Gly Phe Ser Ala Leu Glu Val Asp Glu Thr Tyr Val  
 CGA CCA TGC TTT TCA GCT CTG GAA GTC GAT GAA ACA TAC GTT  
 Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp  
 CCC AAA GAG TTT AAT GCT GAA ACA TTC ACC TTC CAT GCA GAT  
 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Glu  
 ATA TGC ACA CTT TCT GAG AAG GAG AGA CAA ATC AAG AAA CAA  
 Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr  
 ACT GCA CTT GTT GAG CTC GTG AAA CAC AAG CCC AAG GCA ACA  
 Lys Glu Glu Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe  
 AAA GAG CAA CTG AAA GCT GTT ATG GAT GAT TTC GCA GCT TTT  
 Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe  
 GTA GAG AAG TGC TGC AAG GCT GAC GAT AAG GAG ACC TGC TTC  
 Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Glu Ala Val  
 GCC GAG GAG GGT AAA AAA CTT GTT GCT GCA AGT CAA GCT GCC  
 Leu Gly Leu STOP  
 TTA GGC TTA TAA CATCTACATTTAAAGCATCTCAGCCTACCATGAGAATA  
 AGAGAAAGAAAATGAAGATCAAAAGCTTATTCATCTGTTTTCTTTTCGTTGGTG  
 TTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAA  
 TCTAA



European Patent  
Office

# EUROPEAN SEARCH REPORT

0206733

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86304656.1
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	EP - A2 - 0 079 739 (THE UPJOHN COMPANY) * Abstract; claims 5-17 *	1-11, 13-17	C 12 N 15/00 C 07 K 13/00 C 07 H 21/04 C 12 N 1/20
X	EP - A2 - 0 073 646 (GENENTECH, INC.) * Claims 1,3,6,7,9,10,12,14,15; fig. 3 *	1-11, 13-17	C 12 P 21/02 C 12 R 1:19 C 12 R 1:185
X	EP - A2 - 0 091 527 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) * Claims 1-8,14-16; fig. 4 *	1-4,6, 9-17	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 12 N C 07 K C 07 H C 12 P
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 25-08-1986	Examiner WOLF
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



FIG. 3.






FIG. 5.

DIRECT NUCLEOTIDE SEQUENCE DETERMINATION FROM mRNA

(TWO DIFFERENT HUMAN LIVERS)



pGX 401 5' GAA CCT GAG AGA AAT GAA TGC TTC  
3' CTT GGA CTC TCT TTA CTT ACC AAG  
97